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13C NMR has been shown to be a powerful tool for probing the electronic
distribution in paramagnetic hemes and hemoproteins. Methods that can measure the
coordination state and electronic structure of the heme cofactor can be very useful for
mechanistic strudies. The drawback with this technique is the low natural abundance of
13C in the macrocycle, which hinders sensitivity. Advances in the use of recombinant
expression systems have provided us with the resources to selectively label the heme
cofactor of paramagnetic heme-containing proteins and enzymes. However, current
methodologies of replacing the prosthetic heme with 13C labeled heme in P450
apoproteins are not compatible with cytochromes P450 due to their denaturation upon the
removal of the cofactor. We have developed a recombinant expression system, using the
hemoprotein dehaloperoxidase as a model, that allows us to selectively label the heme
cofactor biosynthetically by supplementing aminolevulinic acid (ALA) deficient E. coli
Hu227 cells with synthesized isotopomers of ALA. We have also generated a
recombinant plasmid encoding for CYP102A2 that will be compatible with our novel
expression system, and have preliminary data indicating this method should be very
useful for generating cytochrome P450 samples for 13C analysis.
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CHAPTER I
INTRODUCTION
I.A. Cytochrome P450
Cytochrome P450 enzymes are a family of heme-containing metalloproteins,
which are capable of catalyzing a broad spectrum of oxidation reactions in both
prokaryotes and eukaryotes. This class of enzymes contains a heme iron that is
coordinated to a proximal cysteine thiolate.1 The axial cysteine ligand is responsible for
the characteristic Soret band absorbance at 450 nm upon the formation of the Fe(II)-CO
complex.1,2 Biologically, these enzymes are important because of their unique electronic
properties that give them the ability to catalyze the oxidation of steroids, fatty acids, and
xenobiotics.1-3 
Cytochrome P450 has the ability to activate molecular oxygen. In other words, the
P450 binds to O2, and creates a very powerful and reactive oxygen species through
redistribution of the electron density. Figure I.1 displays the proposed catalytic cycle of
P450. Substrate binds to the active site in the first step, displacing the distal water ligand,
and the heme goes from its ferric hexa-coordinate state to the ferric penta-coordinate
state. A single electron, provided by an auxiliary reductase enzyme, reduces the heme
iron to the ferrous state in the second step; and molecular oxygen binds to oxidize the
metal center in the third step. From here, a second electron is accepted from the reductase
in the fourth step to form the ferric-peroxide complex. This complex is unstable, and is
quickly protonated in a fifth step to form the hydroperoxo-ferric intermediate. Next, in
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the sixth step, a ferryl-oxo porphyrin cation radical intermediate species is formed upon
the delivery of a second proton and a water molecule is released. This radical
intermediate is also known as Compound-I, and is intermediate 6 in the figure. This
intermediate reacts with the bound substrate in the seventh step to form the product,
which is then free to leave the active site to be replaced by water.1
Figure I.1. The P450 catalytic cycle.1
A heme, or iron-protoporphyrin IX, is the cofactor found in the active site of
cytochrome P450 monooxygenase enzymes, giving these enzymes their redox
capabilities.1 It can be seen from Figure I.1 that this heme (shown as FeIII) is where the
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chemistry happens within the active site of this class of enzymes, thus giving the heme a
crucial role in catalysis. The structure of the heme and its numbering system can be seen
in Figure I.2.4 In this system, the common names for the functional groups are used along
with a number indicating its position on the macrocycle. The four meso positions are also
labeled with the Greek letters α, β, δ, and γ. The core carbons refer to the atoms that are
located in the pyrrole rings, including the meso carbons. These core carbons have a
separate system of numbering, where the first and second carbon away from the meso
carbon are called Cα and Cβ respectively. Cm denotes the meso carbons.
4-5 
Figure I.2. Numbering scheme of protoheme IX. 4
I.B. NMR spectroscopic analysis of isotopically labeled heme in hemoproteins
X-ray crystallography has emerged as the premier method for elucidating protein
structure with sufficient resolution to infer mechanistic details concerning enzyme
catalysis. For most proteins this method is perfectly suitable for such structure/activity
studies. P450’s however are somewhat elusive with regard to crystallizability. In fact,
only a handful of crystal structures are currently available for this mega-family of
enzymes. Furthermore, the chemistry is dictated largely by electronic delocalization
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within the macrocyclic porphyrin ring system, a property that as yet cannot be probed
quantitatively using crystallographic methods.
Advances in the use of recombinant expression systems, and improved
spectroscopic methodologies have facilitated the use of 13C-NMR in the analysis of
paramagnetic heme-containing proteins and enzymes. In particular, 13C-labeling of the
heme cofactor provides a method of exploring the electronic structure of P450 enzymes
using NMR spectroscopy. The coordination state and electronic structure of the heme
cofactor is what ultimately dictates its physical and biochemical properties. Additionally,
the heme iron coordination state is often indicative of the spin state. Therefore, one can
use the spin state as a means for probing the ligation state of the heme iron. 4-5 
Although, it is possible to obtain information about the structural and electronic
state of the prosthetic heme using 1H-NMR, this type of spectroscopy has limitations
when probing paramagnetic hemoproteins. One such problem arises because the
delocalization of unpaired electron density is not symmetric. This ultimately causes some
resonances to be resolved from the diamagnetic envelope while others are not, thus
making interpretation of the spectrum more difficult. Problems also arise when heme is in
the reduced form because its substituents lack isotropic shifts. These shifts are left
obscured by the diamagnetic envelope and are also difficult to examine by 1H-NMR.4
Recently, new methods have been developed using recombinant DNA
technologies that allow high levels of 13C and other isotopic labels to be incorporated into
the prosthetic heme of hemoproteins. One study was able to demonstrate the relative ease
with which the coordination state of high-spin heme proteins can be determined from 13C
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NMR data.5 In this study, the 13C-NMR spectra of wild-type sperm whale myoglobin
(sw-Mb) and the mutant sw-Mb H64V, containing 13C isotopomers of their heme, were
compared in their ferric oxidation states. The wild type enzyme is hexa-coordinated in
this state with the four equatorial pyrrole nitrogen ligands from the heme, and axial
positions occupied by a histidine imidizole nitrogen and a water. The histidine (His-93)
ligand is coordinated with the heme iron on the proximal side of the porphyrin ring, and
aids in holding the heme in the active site of the protein. The water ligand is coordinated
with the heme iron on the distal side of the porphyrin ring where substrates bind. A
second histidine (His-64) also located on the distal side of the porphyrin ring helps to
hold the water in its position.
The mutant sw-Mb is penta-coordinated in the ferric oxidation state due to the
lack of the distal His-64 that would normally help to coordinate water in the axial
position. The differences in the two 13C-NMR spectra were the most distinct with respect
to the meso carbon chemical shifts of the heme; where negative chemical shifts were
observed in the wild-type sw-Mb, and positive shifts were observed in the penta-
coordinated mutant sw-Mb. These chemical shifts were used as the diagnostic tool to
determine the coordination state of a recently discovered monomeric periplasmic heme
protein, ShuT, from S. dysenteriae. The coordination state for this new protein had also
recently been suggested to be penta-coordinate from studies using exhaustive
mutagenesis, magnetic circular dichroism, and resonance Raman techniques.6 13C-NMR
data of the ShuT enzyme that had its prosthetic heme replaced with a 13C labeled heme
isotopomer in the ferric oxidation state showed similar chemical shift patterns to the
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mutant sw-Mb. This data was in good agreement with the mutagenesis, magnetic circular
dichroism, and resonance Raman experimental data; suggesting that the coordination
state of ShuT is penta-coordinate. The breakthrough, however, is that this method of
determining the coordination state required only a single 13C-NMR spectrum of the ShuT
enzyme, compared to the multiple techniques required for the previous study with ShuT.
Other newly discovered proteins have been suggested to participate in heme transport,
degradation, and storage. An understanding of the electronic and coordination state
properties could provide evidence for these new proteins’ function.5 Chemical shifts of
the 13C NMR of these proteins may allow these properties to be elucidated. Although
useful for determining coordination states of hemes, a more powerful application of
NMR with regard to hemoprotein analysis is the potential for probing the electronic
distribution within the macrocycle.
Caignan et al. conducted studies with the hydroxide complex of Pseudomonas
aeruginosa Heme Oxygenase containing 13C labeled heme. In this study, an OH- served
as a model for the OOH- ligand of the ferric hydroperoxide intermediate (FeIII-OOH).7
Here it was further demonstrated that the 13C NMR chemical shifts were highly indicative
of the heme electronic structure.
Figure I.3 demonstrates the relationship between 13C chemical shifts and
electronic configurations that were relevant to their study.7 Ferrihemes with the S = 1/2,
(dxy)
2(dxz,dyz)
3 electronic configuration (dπ) have their spin delocalization into the
porphyrin 3e(π) orbital. It can be seen in Figure I.3 that the major electron density is
centered on Cβ in this configuration. That is also expressed through the corresponding
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13C-NMR data of Figure I.3(a), where the Cβ peak is shifted the farthest downfield. The
same logic follows for the Cα and meso carbons (Cm). Cα has a small amount of electron
density corresponding to the small downfield shift, and Cm has a negligible amount of
electron density centered on it; translating into a very small chemical shift. Ferrihemes
with the S = ½, (dxy)
1 electron configuration have their spin delocalization mainly into the
porphyrin 3a2u(π) orbital. This configuration has the most electron density centered on
the Cm carbons and a small amount of electron density centered on the other two core
carbons. This is also supported through the 13C-NMR data in Figure I.3(b), where the
chemical shift corresponding to the Cm carbons is the furthest downfield. It can be seen
that the Cα carbon has a substantial upfield shift where one might expect none, but this is
due to the spin polarization from the Cm core carbons. Finally, ferrihemes with the S =
3/2 spin state show downfield shifts in the 13C-NMR data that are consistent with a large
amount of electron density centered on the Cα and Cβ core carbons. The substantial Cm
chemical shift is due to spin polarization from the nearby Cα core carbons, as the Cm
orbital has no electron density.
8
Figure I.3. Left; Typical porphyrin core 13C chemical shifts for (a) FeIII-porphyrinates
with the S = ½, dπ electron configuration, (b) Fe
III-porphyrinates with the S = ½, (dxy)
1
electron configuration, and (c) FeIII-porphyrinates with the S = 3/2, (dxy)
2(dxz,dyz)
2(dz2)
1.
Right; Schematic representation of the 3a2u(π) and 3e(π) porphyrin orbitals. Relative
circle sizes correspond to the calculated electron density at that position.7
Researchers conducting the study on Heme Oxygenase used the data in Figure I.3
as a tool for characterizing the spin states, and electronic configurations of their FeIII-OH
model for the ferric hydroperoxide intermediate. With this data and their own, they were
ultimately able to show that the most abundant spin population exhibited a spin crossover
between S = ½, (dπ) and S = 3/2 spin states. They also identified two less populated spin
states that were pure S = 3/2 and S = ½, (dxy)
1 electronic configurations, and stated that
the relative populations of these configurations were indicative of nonplanar
deformations of the macrocycle, in particular the exocyclic vinyl groups. Finally, they
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concluded that abundant spin density centered at the Cm core carbons, taken with the
nonplanarity of the porphyrin ring, “primes the macrocycle to actively participate in its
own hydroxylation.”7 They also stated that their conclusion was only valid if the ligand
field strength of the coordinated OOH- was modulated in a similar manner as their model
system. This study is a perfect illustration of the power of 13C-NMR spectroscopy in the
analysis of heme containing proteins.
We would ultimately like to conduct studies such as the ones mentioned above
using various cytochrome P450 enzymes. However, a fundamental problem had to be
overcome for this to become a possibility. The hemoproteins analyzed in the studies
mentioned above as well as the cytochrome P450 enzymes we are interested in studying
contain a natural abundance of 13C that is much too low to be useful for 13C-NMR
spectroscopy given their metal centers. The studies mentioned above used reconstitution
techniques to generate proteins containing labeled prosthetic heme cofactors.
Unfortunately, in cytochrome P450 enzymes, the native heme is not easily removed and
reincorporated without destroying the enzyme.
We have devised an expression system that allows high levels of 13C
incorporation into the prosthetic heme cofactor of hemoproteins using a mutant strain of
Escherichia coli (E. coli) called Hu227. This system takes advantage of the biosynthesis
of the heme to achieve 13C incorporation. In order to use this expression system, we
needed to generate new expression vectors because ours required the presence of a T7
polymerase. Hu227 contains no T7 polymerase gene naturally, and attempts to transfect
these cells with the T7 polymerase gene separately from the protein expression vector
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had been unsuccessful previously. We decided to generate a new expression vector that
was regulated by a lac promotor and contained the CYP102A2 gene. In the interim, we
generated 13C-NMR hemoprotein samples using a vector that encoded for
dehaloperoxidase that was under the control of a lac promoter. This was to primarily
serve as a model system to ensure that we could isotopically label the prosthetic heme
cofactor using our expression system.
I.C. Escherichia coli Hu227
We used the mutant strain of Escherichia coli (E. coli) Hu227 in our expression
of dehaloperoxidase due to its inability to synthesize aminolevulinic acid (ALA)
naturally. This particular strain of E. coli contains a mutation in the hemA gene, which
encodes for glutamyl-tRNA.8 Glutamyl-tRNA is required for the biosynthesis of ALA,
which is the first precursor in the biosynthesis of heme. By synthesizing several
isotopomers of 13C ALA and 15N ALA from labeled glycine and supplying it to the
Hu227 cells that are unable to produce aminolevulenic acid naturally, it was possible to
achieve high-level incorporation of 13C or 15N into the heme of dehaloperoxidase via the
biosynthetic pathway of the heme cofactor shown in Figure I.4.4
The biosynthesis of heme begins with the condensation of two δ-aminolevulinic
acid (ALA) molecules. This step is catalyzed by ALA dehydratase enzyme, forming
porphobilinogen (PBG). Next, four PBG molecules are condensed by PBG deaminase
forming a 1-hydroxylmethyl bilane (HMB) intermediate. This intermediate is
subsequently cyclized by uroporphyrinogen III synthase forming uroporphyrinogen III
(Uro’gen). The four acetate groups on uroporphyrinogen III are selectively cleaved by
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the Uro’gen decarboxylase yielding coproporphyrinogen III (Copro’gen). The propionate
groups located on pyrroles I and II undergo oxidative decarboxylation by Copro’gen
oxidase, yielding protoporphyrinogen IX. Subsequently, protoporphyrinogen IX oxidase
carries out the oxidation of protoporphyrinogen IX by removal of six hydrogen atoms to
give protoporphyrin IX. The final step in the biosynthesis of heme, which is not shown
in Figure I.4, is the insertion of Fe2+ into the macrocycle by ferrochelatase.9
Figure I.4. The biosynthetic pathway of heme from [5-13C] aminolevulinic acid. The
highlighted atom represents 13C.4
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Utilizing specific isotopomers of the biosynthetic precursor ALA we can control
the selective isotopic labeling of the heme cofactor. Figure I.5 shows the predicted
labeling patterns generated biosynthetically from each of the three isotopomers of ALA
used in our research.4-5, 9 Starting with [4-13C] ALA, only certain Cα and Cβ core carbons
would be isotopically labeled. No Cm core carbons should be labeled in the heme. Starting
with [5-13C] ALA, it can be seen in the figure that no Cβ core carbons would be
isotopically labeled, but all of the Cm carbons should be
13C. Finally, starting with [15N]
ALA, a heme where only the nitrogen atoms are labeled is expected. However, before
any protein with labeled heme could be expressed, the isotopomers of ALA needed to be
synthesized.
Figure I.5. 13C and 15N labeling patterns generated when heme is biosynthesized from [4-
13C] ALA, [5-13C] ALA, and [15N] ALA.4-5 
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I.D. Synthesis of the isotopomers of aminolevulinic acid
The method that we chose for the synthesis of the aminolevulinic acid (ALA)
isotopomers was the procedure of Wang and Scott because of the reported efficiency and
economy of the four individual steps.10 The reaction scheme for the total synthesis of
ALA from the starting material glycine is shown in Figure I.6.10 In this method, the
starting material glycine is protected by phthalic anhydride in the first step followed by
treatment with thionyl chloride to yield the acetyl chloride. The subsequent step in the
reaction was the key step, and it required that the acetyl chloride be coupled with the zinc
homoenolate using a palladium catalyst to form phthalimidolevulinic acid ethyl ester.
However, before this reaction could proceed, the zinc homoenolate had to be synthesized
by reacting [(1-ethoxycyclopropyl)-oxy]trimethylsilane with ZnCl2 in ether. The zinc
homoenolate exists as an etherate and is shown in Figure I.7.11 Once synthesized, the zinc
homoenolate of alkyl propionate can react with the carbonyl carbon of the
phthalimidoacetyl chloride in a carbon-carbon bond forming reaction to yield the
phthalimidolevulinic acid ethyl ester. Deprotection can then proceed by the acid
hydrolysis of phthalimidolevulinic acid ethyl ester with hydrochloric acid to yield the
final product, ALA. In this synthesis [1-13C] glycine may be used as the starting material
to ultimately generate [4-13C] ALA, [2-13C] glycine can be used to generate [5-13C] ALA,
and [15N] glycine can be used to generate [15N] ALA.
14
Figure I.6. The synthetic procedure for the generation of unlabeled ALA, [4-13C] ALA,
[5-13C] ALA, and [15N] ALA.10
Figure I.7. Synthesis of zinc homoenolate.11
OSiMe3
OEt
ZnCl2
Et2O
Zn(CH2CH2COOEt)2 * (Me3SiCl)2
Zn O
OEt
COOEt
Et2O
+
Etherate
I.E. Dehaloperoxidase
Selection of dehaloperoxidase (DHP) for these studies was based on the
availability of an effective expression vector for this moderately sized hemoprotein
(~31 kDa)12 that was under the control of a lac promoter. Amphitrite ornate is a
polychaete worm that has the capability of surviving in estuarine mud flats that are
15
contaminated with halophenols. Although such compounds have been widely dispersed
by humans, and constitute a significant environmental problem, these compounds are also
generated as a sort of chemical warfare by other marine organisms.13-15 Enzymes
involved in the breakdown of halophenols would be appealing to study for the purpose of
bioremediation. DHP is the globular heme-containing enzyme that provides this marine
worm with its unique ability of catalyzing the oxidative dehalogenation of noxious
halogenated phenols in the reaction shown in Figure I.8.16 It can also be seen in the figure
that H2O2 is required to catalyze the dehalogenation of the trihalogenated phenols, but
DHP is also capable of oxidizing mono- and dihalogenated phenols as well, which are not
shown.13, 15
Figure I.8. Reaction catalyzed by dehaloperoxidase of Amphitrite ornate.16
In recent studies using UV-Visible absorption and magnetic circular dichroism, it
has been demonstrated that exogenous ligand-free ferric DHP is hexa-coordinate with a
distal water and a proximal neutral histidine as axial heme ligands.16 This coordination
state is distinct from other ferric resting state histidine ligated peroxidases, which activate
peroxide through a mechanism involving an electronic push-effect initiated by a partially
16
ionized proximal histidine ligand. We have successfully incorporated 13C into a variety of
different positions in the heme of DHP using a recombinant expression system, and have
also been able to incorporate 15N into the heme as well. With these samples, future
studies using 13C-NMR and 15N-NMR should be possible in order to characterize the
coordination state of the exogenous ligand-free ferric resting state of DHP. This would
further demonstrate the power and validity of this method in the characterization of heme
coordination states. Perhaps more importantly, we can also use these samples to probe the
electronic configuration of the heme in various oxidation states. Studies of the electronic
configurations of the heme are not accomplished in a simple fashion by any other
method, and to our knowledge no such studies have been conducted on this particular
enzyme.
I.F. Cytochrome P450102A2
While attempting to generate dehaloperoxidase containing a labeled heme, a
separate project was also underway where we were ultimately able to clone the
CYP102A2 gene of Bacillus subtillis 168 (B. subtillis). The P450 CYP102A2 is one of
eight P450s encoded by B. subtillis.17, 25 Additionally, CYP102A2 is a homolog of
CYP102A1, which is the flavocytochrome P450 BM3 encoded by Bacillus Megaterium.
CYP102A2 also shares the rare characteristic of containing each of the cofactors flavin
adenine dinucleotide (FAD), flavin mononucleotide (FMN), and heme. It has also been
demonstrated that this enzyme binds and catalyzes the hydroxylation of a range of long-
chain fatty acids.18-20
17
Keeping in mind that we wanted to be able to express the CYP102A2 in Hu227
cells, we followed a modified version of the cloning method described by Gustafsson et
al.17 This procedure required the ligation of the CYP102A2 gene into the pBluescript II
SK(-) vector (Stratagene), which is shown in Figure I.9.21 It can be seen from the vector
map in the figure that the multiple cloning site is under the control of a lac promoter,
which eliminated the need for a T7 polymerase. Therefore, cloning into this vector made
CYP102A2 expression more compatible with our Hu227 cells. In future studies, the
compatibility will allow us to eventually overexpress the CYP102A2 with isotopically
labeled heme for 13C-NMR studies as discussed earlier. The optimization of growth
conditions for the enzyme in our expression system would need to be worked out using
unlabeled aminolevulinic acid prior to any experiment using the more expensive
isotopomers of the aminolevulinic acid.
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Figure I.9. Vector map and sequences of pBluescript II SK (-).21
In the current study, our goal was to be able to express and purify the CYP102A2
enzyme from Hu227 cells after cloning was accomplished. Then we wanted to assay its
activity towards the substrate p-Nitrophenoxydodecanoic acid (12-pNCA). We followed
the method described by Schwaneberg et al., where the NADPH dependent hydroxylation
of 12-pNCA by the P450 was monitored via product formation spectrophotometrically.18
Figure I.10 displays the reaction that is catalyzed by the CYP102A2 homologue P450
BM-3 F87A.
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Figure I.10. Reaction scheme of p-nitrophenoxycarboxylate (pNCA) conversion by P450
BM-3 F87A. The formation of p-nitrophenolate is monitored at 410 nm.18
In this research project, we were able to successfully synthesize and characterize
three isotomomers of aminolevulinic acid (ALA): [4-13C] ALA, [5-13C] ALA, and [15N]
ALA. These three isotopomers were used in the expression of the hemoprotein
dehaloperoxidase (DHP) in E. coli Hu227 cells, which were incapable of synthesizing
their own ALA. We were able to show through analytical techniques, that high levels of
13C and 15N were incorporated into the heme of DHP. We also generated a CYP102A2
expression vector that was under the control of a lac operon. This was done in order to
create a P450 expression vector that was compatible with our expression system. This
will enable future heme labeling studies to be performed on this enzyme. Overexpression
of the generated CYP102A2 expression vector was accomplished in E. coli Hu227 cells,
20
and an activity assay was conducted with the enzyme and 12-p-nitrophenoxycarboxylic
acid.
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CHAPTER II
EXPERIMENTAL
II.A. Synthesis of 13C and 15N δ-aminolevulinic acid (ALA) isotopomers
[1-13C] glycine, [2-13C] glycine, and [15N] glycine were purchased from
Cambridge Isotope Laboratories, Inc. All other chemicals used were obtained from
Aldrich, Fisher Scientific, Acrōs, and Pharmco. [4-13C] Aminolevulinic acid (ALA), [5-
13C] ALA, and [15N] ALA were each prepared via the synthetic procedure described by
Wang and Scott 10. Only the starting material glycine was varied in each case; [1-13C]
glycine was used in the synthesis of [4-13C] ALA, [2-13C] glycine was used in preparing
[5-13C] ALA, and [15N] glycine was used in the synthesis of [15N] ALA. Moisture
sensitive reactions were always carried out under an atmosphere of nitrogen or argon gas,
and moisture sensitive liquid reagents were always delivered to reactions via syringe.
Only round bottom flasks and medium length condensers with 14/20 joints were used
during reactions to prevent excessive loss of solvents. Diethyl ether was kept dry in a
solvent purification system, and was used immediately after being dispensed.
Characterization of products was done using nuclear magnetic resonance spectroscopy,
and was carried out on a JEOL JNM-ECA500 FT NMR system. The mole values,
reaction yields and NMR data given in this procedural section, in order to avoid
confusion, are for reagents and products in the synthesis of [5-13C] ALA.
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II.A.1 Isotopomers of phthalylglycine
[2-13C] glycine (99 atom% 13C, 1.010 g, 13.28 mmol) was reacted with phthalic
anhydride (1.992 g, 13.45 mmol) in a 50 mL round bottom flask using indirect heat over
a Bunsen burner with gentle swirling under a stream of dry argon gas. Heating caused the
white powders to liquefy and simmer lightly until solid crystals began forming on the
inner sides of the flask. Heating was continued for 2 minutes after solids began forming.
The resulting off-white solid was recrystallized from water, yielding [2-13C]
phthalylglycine as white needles (2.470 g, 90.2%); 1H-NMR (DMSO) δ 4.28 (d, 1J =
141.8, 2H, 13CH2CO), 7.88 (AA’BB’, 4H, H-Ph). Product was dried in an oven at 100
oC
and stored in a desiccator at room temperature.
II.A.2 Isotopomers of phthalimidoacetyl chloride
Dried, [2-13C] phthalylglycine (2.388 g, 11.58 mmol) was refluxed for 18 hours in
thionyl chloride (12.0 mL, 165.2 mmol) in a 25 mL round bottom flask equipped with a
Teflon coated magnetic stir-bar and a reflux condenser. The reaction proceeded under
continuous argon gas flow in an 80 oC oil bath. The resulting orange liquid was allowed
to cool, and thionyl chloride was removed with a BÜCHI Rotovapor R-200. Excess
thionyl chloride was removed from the resulting dried yellow solid by dissolving in dry
diethyl ether and evaporating the solvent (2 x 10 mL), which left [2-13C]
phthalimidoacetyl chloride behind as a yellow powder (2.557 g, 98.3%); 1H-NMR
(CDCl3) δ 4.82 (d, 1J = 146.3, 2H, 13CH2CO), 7.85 (AA’BB’, 4H, H-Ph). The acid
chloride was stored at room temperature for up to two weeks.
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II.A.3 Isotopomers of phthalimidolevulinic acid ethyl ester
The next step required the synthesis of zinc homoenolate to be used in a
subsequent reaction with the phthalimidoacetyl chloride. Zinc chloride (2.046 g, 15.01
mmol) was fused in a 100 mL round bottom flask under vacuum with indirect heat over a
Bunsen burner. This was allowed to cool under vacuum to a white solid and was used
immediately. Next, the zinc chloride was stirred at room temperature under argon gas
flow in dry diethyl ether (30 mL) in the 100 mL flask equipped with a reflux condenser.
Once a clear homogenous mixture was obtained, dry [(1-ethoxycyclopropyl)-
oxy]trimethylsilane (6.0 mL, 30 mmol) was added to the reaction drop wise with a
syringe over a 5-minute period to give a cloudy solution. Stirring continued at room
temperature for 1 hour followed by refluxing in a hot oil bath for 30 minutes to generate
the crude zinc homoenolate.
The zinc homoenolate solution was stirred in an ice water bath under an
atmosphere of argon gas. Tetrakis(triphenylphosphine)palladium(0) (148 mg, 0.128
mmol) and [2-13C] phthalimidoacetyl chloride (2.413 g, 10.74 mmol) were added to the
stirring solution all at once. Once a homogenous mixture was obtained, N, N-
dimethylacetamide (3 mL, 32 mmol) was added slowly via syringe. These components
were allowed to stir at 0 oC under argon gas flow for 1 hour and continued stirring at
room temperature for 2 hours.
This mixture was evaporated down to a light brown residue, and was then
dissolved in 100 mL of dichloromethane. The solution was transferred to a 250 mL
separatory funnel and was washed with 50 mL of water to quench the reaction. The
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aqueous fraction was discarded and the dichloromethane was washed with 50 mL of
water saturated with NaCl. The organic fraction was saved and dried overnight over
sodium sulfate in a 125 mL Erlenmeyer flask capped with a rubber septum. The clear
orange solution was evaporated down to a deep orange colored solid under vacuum. This
was recrystallized from ethanol to yield the [5-13C] phthalimdolevulinic acid ethyl ester
as light yellow crystals (2.706 g, 90.5%); 1H-NMR (CDCl3) δ 1.25 (t, 3J = 7.4, 3H,
OCH2CH3), 2.65 (t,
3J = 6.7, 2H, COCH2CH2), 2.84 (t,
3J = 6.4, 2H, COCH2CH2), 4.14
(q, 3J = 7.3, 2H, OCH2CH2), 4.55 (d,
1J = 139.3, 2H, 13CH2CO), 7.80 (AA’BB’, 4H, H-
Ph).
In some cases, it was not possible to evaporate the crude product sufficiently
enough to generate a dried solid. This was due to excess N, N-dimethylacetamide. In
these cases, the evaporated crude product was applied to a large flash column. The
desired product was separated from impurities with a 1:1 mix of ethyl acetate:hexane and
the eluent was collected in several fractions. Fractions containing the labeled
phthalimidolevulinic acid ethyl ester were identified using thin layer chromatography.
The fractions containing the desired product were pooled and evaporated down to a
yellow solid. This was washed several times with chloroform to remove excess ethyl
acetate. This provided sufficiently pure product, and further recrystallization was not
necessary.
II.A.4 Isotopomers of δ-aminolevulinic acid
[5-13C] aminolevulinic acid was produced from the acid hydrolysis of [5-13C]
phthalimidolevulinic acid ethyl ester. [5-13C] Phthalimidolevulinic acid ethyl ester (2.662
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g, 9.57 mmol) was placed in a 50 mL round bottom flask and was refluxed overnight in a
1:1 mix of hydrochloric acid: acetic acid at 120 oC. The resulting deep yellow solution
was evaporated to dryness. The resulting solid was washed with 20 mL of water to
remove excess acid and an off-white solid was left behind after evaporation. This was
taken up in 40 mL of water and was transferred to a 125 mL separatory funnel. The
aqueous fraction was washed with (4 x 25 mL) ethyl acetate to remove phthalic acid. The
aqueous fraction was saved and concentrated down to a brown oily residue with
evaporation under vacuum. Finally, labeled aminolevulinic acid (ALA) was recrystallized
from ethanol and diethyl ether. This was done by dissolving the ALA in hot ethanol in a
round bottom flask. The solution was placed on ice, and cold diethyl ether was added
drop-wise until white solid crystals of ALA precipitated out of solution; (1.506 g, 93.3%)
1H-NMR (D2O) δ 2.53 (t, 3J = 6.2, 2H, COCH2CH2), 2.73 (, 2H, COCH2CH2), 3.95 (d, 1J
= 143.3, 2H, 13CH2CO). Isotopomers of ALA were stored separately at –20
oC in brown
glass vials. The overall yield was 67.2%.
II.B. Agar plate preparation: for growth of E. coli and expression of recombinant
proteins
Agar components included 5 g of tryptone, 5 g of NaCl, 2.5 g of yeast extract, and
7.5 g of agar. These components were poured into a 1000 mL Erlenmeyer flask and
equipped with a magnetic stir bar. Deionized water was added and stirred to mix the
components on a tabletop magnetic stirrer. The pH was adjusted to 7.4 with 1M NaOH,
and the solution was brought up to a final volume of 500 mL with additional deionized
water. The Erlenmeyer flask was covered with aluminum foil and was autoclaved for 16
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minutes. The hot agar solution was placed back on the tabletop magnetic stirrer, and was
allowed to cool while stirring until the outside of the flask was just warm to the touch.
When required, ampicillin trihydrate 50 mg (0.1 g/L) and aminolevulinic acid 10 mg
(0.02 g/L) were added using sterile techniques and stirred to homogeneity. This solution
was then used to fill sterile culture plates. The filled plates were covered and allowed to
cool to room temperature to harden the agar. The plates were stored at 4 oC for up to four
weeks.
II.C. Preparation of Luria-Bertani (LB) broth
LB broth components included 10 g of tryptone, 10 g of NaCl, and 5 g of yeast
extract. These components were poured into a 1000 mL beaker and equipped with a
magnetic stir bar. Deionized water was added and stirred to dissolve the components on a
magnetic stirrer. The pH was adjusted to 7.4 with 1 M NaOH, and the final volume was
brought up to 1000 mL with additional deionized water. The solution was further mixed
to homogeneity and transferred to a 2.8 L Fernbach flask. This flask was covered with
aluminum foil and then autoclaved for 16 minutes. The LB broth was then cooled to
room temperature. When required, each liter of cooled broth received 0.100 g of
ampicillin trihydrate and 0.020 g of appropriately labeled aminolevulinic acid. The flask
remained covered with aluminum foil after addition of ampicillin and aminolevulinic
acid. LB broth was used within three days after preparation.
II.D. Preparation of Terrific Broth (TB)
TB broth components included 12 g of tryptone, 24 g of yeast, and 4 mL of
glycerol. These components were poured into a 1000 mL beaker and equipped with a
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magnetic stir bar. Deionized water was added and stirred to dissolve the components on a
magnetic stirrer. The final volume of the solution was brought up to 900 mL, and further
mixed to homogeneity. This solution was transferred to a 2.8 L Fernbach flask and was
covered with aluminum foil.
Phosphate buffer was prepared separately by weighing out 2.32 g of monobasic
potassium phosphate, and 16.43 g of dibasic potassium phosphate. These masses were
then transferred to a 125 mL Erlenmeyer flask. Next, the potassium salts were dissolved
in deionized water, and the final volume was brought up to 100 mL with additional
deionized water. Finally, the flask was covered with aluminum foil.
The aluminum foil covered 2.8 L Fernbach flask and 125 mL Erlymeyer flask
were both autoclaved for 16 minutes. These two components were allowed to cool to
room temperature, and the 100 mL of phosphate buffer was added to the 900 mL solution
in the Fernbach flask. The Fernback flask was immediately covered with the sterile
aluminum foil. It is important to keep the phosphate buffer separate from the other
components while autoclaving and cooling in order to prevent the formation of
precipitates. When required, each liter of cooled broth received 0.100 g of ampicillin
trihydrate and 0.020 g of appropriately labeled aminolevulinic acid. Antibiotics and
aminolevulinic acid were only added in the moments prior to inoculation, and the flask
remained covered with aluminum foil after addition of ampicillin and aminolevulinic
acid. TB broth was used within 3 days after preparation.
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II.E. Preparation of competent HU227, HB101, and XL1-Blue cells
Escherichia Coli HU227, HB101, and XL1-Blue cells were made competent
separately, using the same method. Sterile techniques were used throughout these
preparative steps. Frozen stock cells were used to inoculate 25 mL of sterile LB broth
contained in a 50 mL Falcon tube using a sterile wooden stick. When preparing
competent HU227 cells, less than 1 mg of unlabeled aminolevulinic acid was also added
to the inoculated growth media. The Falcon tube was then placed on its side in a New
Brunswick Scientific C24 Incubator Shaker overnight, shaking at 240 rpm and 37 oC. The
next day, 20 µl of the overnight culture was used to inoculate another 25 mL of LB
media, and unlabeled aminolevulinic acid was added in the case of HU227 cells. This
Falcon tube was placed in the shaker at the same settings and incubated for 4 to 5 hours
with shaking. Next, 6 mL of the culture was transferred to a sterile, 15 mL Falcon tube,
and was centrifuged at 5,000 rpm, for 12 minutes at 4 oC (these settings were used at each
centrifuge step). The supernatant was discarded and the pellet was resuspended into 2 mL
of ice cold, sterile 100 mM MgCl2. After five minutes of incubation on ice, the cells were
centrifuged again. The supernatent was discarded and the cells were resuspended in 2 mL
of ice cold, sterile 100 mM CaCl2. Cells were then incubated on ice for 45 minutes. The
suspension was centrifuged again and decanted. Finally, the pellet was resuspended in 1
mL of ice cold, sterile 85 mM CaCl2 with 15% glycerol. This suspension was kept on ice
and was used immediately for transformations.
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II.F. Transformation of E. coli Hu227, HB101, and XL1-Blue cells
First, 200 µl of freshly made competent cells were transferred to a sterile 1.5 mL
microfuge tube that had been chilled on ice, followed by the addition of 5 µl of the
plasmid to be transformed into the cells. The microfuge tube was gently tapped several
times to mix, and the tube was immediately placed back on ice for 10 minutes. Next, the
microfuge tube was transferred to a water bath at exactly 42 oC, and was allowed to
incubate for exactly 1 minute. After incubation the microfuge tube was replaced on ice
for an additional 2 minutes. Finally, 800 µl of ice cold, sterile LB broth containing no
antibiotics was added to the microfuge tube.
The microfuge tube was placed in a New Brunswick Scientific C24 Incubator
Shaker for between 1 and 2 hours, shaking at 240 rpm and 37 oC. Next, 100 µl aliquots of
the cell suspension were spread onto LB agar plates, which contained ampicillin in the
case of XL1-Blue and HB101 cells. Growth plates required both ampicillin and unlabeled
aminolevulinic acid in the case of HU227 cells. The inoculated plates were incubated in
an oven at 37 oC overnight, or until colonies were formed.
II.G. Expression of dehaloperoxidase with isotopically labeled heme in HU227 cells
A single colony was picked from a LB plate containing HU227 cells, which had
been transformed the previous day with a stock plasmid encoding for the
dehaloperoxidase (DHP) gene that was under control of a lac promoter. The colony was
picked from the plate under sterile conditions using a sterile stick, and the colony was
used to inoculate 25 mL of LB broth in a 50 mL Falcon tube containing ampicillin and
unlabeled aminolevulinic acid. This tube was placed on its side in a New Brunswick
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Scientific C24 Incubator Shaker overnight, shaking at 240 rpm and 37 oC. The next day,
250 µL aliquots of the overnight culture were used to inoculate four separate 2.8 L
Fernbach flasks containing 1 L of LB broth. Ampicillin trihydrate and either [4-13C]
ALA, [5-13C] ALA, or [14N] ALA had been added to each flask of LB broth after
sterilization of the media as explained previously. Each liter of inoculated broth was
covered with aluminum foil and was placed in a New Brunswick Scientific C25KC
Incubator Shaker and incubated at 24.5 oC with shaking at 207 rpm. Shaking continued
for two days or until a 1 mL aliquot of culture had an A600 equal to 1.7 or greater.
Cultures were also tested for expression of DHP using UV-Vis spectrophotometry.
Protein was harvested from cultures displaying expression.
II.H. Dehaloperoxidase harvest and protein purification
Cell cultures testing positive for DHP over-expression were transferred to 500 mL
centrifuge tubes. The cultures were centrifuged in a Beckman Avanti J-25 centrifuge at
9,500 rpm at 4 oC for 30 minutes using a JA 10 Beckman rotor. The supernatant was
discarded, and the pellet was resuspended and homogenized in 100 mL of pH 5.0, 50 mM
phosphate equilibration buffer. Cell walls were lysed with lysozyme for 20 minutes at
room temperature while stirring. The lysed cells were transferred to 40 mL centrifuge
tubes and the membranes were degraded by sonication using a Fisher Scientific 60 Sonic
Dismembrator while on ice, in four 30-second bursts, and at a power of 20W. The 25 mL
centrifuge tubes were transferred to a JA-20 Beckman rotor and centrifuged at 19,000
rpm for 30 minutes at 4 oC. Supernatant containing the DHP was decanted and saved,
while the cell fragments were discarded. DHP concentration was determined by UV-Vis
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spectrophotometry of the CO-reduced heme of DHP, and the crude protein was then
stored at -80 oC or immediately purified.
Next, the pH of the cell-free extract was readjusted to 5.0 by adding 1M HCl
drop-wise. The crude protein was transferred to 40 mL centrifuge tubes and centrifuged
again in a JA-20 Beckman rotor under the previous conditions. The supernatant was
passed through a purification column containing Whatman pre-swollen DE52
diethylaminoethyl cellulose that had been equilibrated previously using about 5 column
volumes of 50 mM phosphate buffer at pH 5.0. DHP passed through the purification
column in a chromatography refrigerator at 4 oC, and impurities bound to the solid phase
through electrostatic interactions.
The flow-through was collected and transferred to a Millipore Stirred
Ultrafiltration Cell 8200 equipped with a Millipore Ultrafiltration Membrane YM1
(NMWL:1 kDa). The protein sample was concentrated down to a final volume of 15 mL
while stirring in the refrigerator at 4 oC. The sample was further concentrated down, at 4
oC, to a volume of 2 mL using a Millipore Centriprep YM-3 (NMWL:3kDa) in a Fisher
Scientific Centrific Centrifuge spinning at 4,000 rpm.
The 2 mL of concentrated crude DHP was further purified by size exclusion
chromatography using a Sephacryl S200 (Pharmacia) column. The column had been
equilibrated previously using 800 mL of 50 mM phosphate buffer at pH 5.0, and the DHP
sample was run through at 4 oC. The protein moved through the column as a tight dark
red or brown band. The protein was collected in 2 to 3 mL fractions as it eluted.
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Collected protein fractions were tested for purity of DHP by spectrophotometry
without further treatment using a Varian CARY 100 Bio UV-Visible Spectrophotometer.
The samples were scanned from 250 nm to 500 nm in baseline subtraction mode against
water. Fractions that contained an absorbance ratio of 1:3, at 280 nm and 418 nm
respectively, were concentrated to at least 0.2 mM, which was determined by the CO-
reduced spectrum of DHP. Enough glycerol was added to the concentrated, pure DHP
samples to yield a 10% glycerol final concentration before freezing the samples in a
-80 oC freezer. Impure fractions were stored separately at -20 oC to be used for heme
extractions at a later time.
Lastly, all purification columns were washed with about 4 column volumes worth
of 20% ethanol after each protein purification procedure in order to clean the columns of
impurities and residual protein. These washing were collected and saved separately at -20
oC according to the labeled heme content. These washings were used at a later time for
heme extractions.
II.I. DHP assay via UV-Vis spectrophotometry of the CO-reduced heme
The concentration of DHP in Hu227 cells was found using a variation of the
method described by Omura and Sato22 for detection of the hemoprotein, cytochrome
P450. The extinction coefficient was assumed to be ε418= 193 mM-1 cm-1, and the
concentration of DHP was determined from the absolute spectra of the reduced CO
complex.27
The DHP concentration in intact cells was determined by centrifuging a 2 mL
aliquot of cultured cells from the Fernbach flask in a Fisher Scientific Centrific
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Centrifuge spinning at full speed for 10 minutes at 4 oC. The growth broth was discarded
by decanting and the cell pellet was resuspended in 2 mL of 50 mM phosphate buffer at
pH 7.4. One quartz cuvette was filled with deionized water and placed in the sample
compartment of a Varian CARY 100 Bio UV-Visible Spectrophotometer. A baseline
spectrum was recorded on the deionized water from 400 nm to 500 nm. Next,
approximately 5 mg of sodium dithionite (Sigma) was dissolved in the 2 ml cell
suspension to reduce the prosthetic heme iron of DHP. Carbon monoxide gas was slowly
bubbled through the cell suspension for one minute to form the reduced heme iron-CO
complex, and 1 mL was transferred to another quartz cuvette. The water filled cuvette
was transferred to the reference compartment of the spectrophotometer, and the cuvette
containing the cell suspension was placed in the sample compartment. The absorbance
spectrum of the reduced CO complex of DHP was recorded from 400 nm to 500 nm with
the baseline subtracted. The reduced heme iron-CO complex of DHP absorbed at 418 nm.
The DHP concentration in crude, cell-free extract was determined by diluting a
100 µL aliquot of the extract up to 1 mL with 50 mM phosphate buffer at pH 5.0. Next,
the sample was gently bubbled with carbon monoxide for 1 minute, followed by the
addition of a few grains of sodium dithionite. The spectrum of the reduced heme iron-CO
complex of DHP was then recorded from 400 nm to 500 nm with a baseline spectrum of
deionized water subtracted. The procedure for finding the concentration of DHP in
concentrated, purified samples was identical to that of the crude extract except that a 10
µL aliquot of purified sample was diluted up to 1 mL in this assay.
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II.J. Preparation of dehaloperoxidase for 1H and 13C NMR
NMR samples of DHP, which had been overexpressed in growth media
containing [5-13C] aminolevulinic acid, were prepared using 1 µmole of the hemoprotein.
The protein was concentrated down to about 2 mL with a Millipore Centriprep YM-3
(NMWL:3kDa), in a Fisher Scientific Centrific Centrifuge spinning at 4,000 rpm.
Potassium ferricyanide was added (100 µmole) to oxidize all heme iron in the protein
sample. The 2 mL sample was applied to a desalting column (Sephacryl S200 by
Pharmacia) that had been equilibrated with four column volumes of 50 mM phosphate
buffer at pH 5.0. The brown protein separated well from the bright yellow complex salt.
The oxidized protein fraction was saved and concentrated to 1 mL. Next, the aqueous
phosphate buffer was exchanged with 50 mM phosphate at pH 5.0 in D2O. This was
accomplished by a 1:6 dilution of protein to phosphate buffer in D2O, followed by
concentrating the sample. This was repeated twice more to bring the theoretical
concentration of H2O in the sample down to less than 0.5%.
II.K. Extraction and purification of labeled prosthetic heme from dehaloperoxidase
Heme extractions from DHP were conducted using a variation of the method
described by Teale and Yonetani23,24. 13C and 15N labeled heme samples from DHP were
obtained by first thawing the 20% ethanol column washings as well as the impure size
exclusion column fractions. These samples were pooled according to the labeled heme
content. Next, the pH was adjusted to 2.0 with 1 M HCl in order to denature protein and
release heme into solution. The resulting pink slurry was divided into glass test tubes, and
equal volumes of butanone were added to each tube to pull free heme out of the aqueous
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phase. The tubes were shaken vigorously for about a minute and then centrifuged at 4 oC
for 45 minutes in a Fisher Scientific Centrific Centrifuge spinning at 8,000 rpm. After
centrifugation, the organic layer containing the heme was pulled off of the separate
aqueous phase. The addition of butanone, followed by shaking and centrifugation was
repeated on the aqueous phase (2x).
Next, the butanone fraction was lyophilized, and dried crude heme was dissolved
in a small amount of methanol. The solution was then diluted with water to bring the
methanol concentration down to 30%. Additionally, enough glacial acetic acid was added
to the solution to yield about a 0.1% concentration. This 30% methanol solution was
passed through a pre-equilibrated Sep-Pak C18 3cc column (Waters) in order to apply the
labeled heme to the solid phase. About 10 mL of additional 30% methanol with 0.1%
acetic acid was passed through the column after the application of heme. Finally, a
concentrated brown band of heme was eluted using methanol. The methanol was
lyophilized to leave a dried heme sample. These dry samples were stored in the freezer at
-20 oC until they were used for preparing NMR and MALDI-TOF samples.
II.L. Preparation of isotopically labeled heme samples for NMR analysis
Dry heme samples were removed from the freezer, and were washed and dried
from a few milliliters of pyridine several times to ensure that all of the methanol was
removed. The dried sample was taken up in pyridine-d5 (Cambridge Isotope
Laboratories, Inc.), and an equimolar amount of stannous chloride was added in order to
insure that all heme was reduced in the sample. Samples were then ready for NMR
analysis.
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II.M. Preparation of heme samples for MALDI-TOF analysis
Dry heme samples were removed from the freezer, and were each diluted up to
100 µL with methanol. These solutions were used to make 1:10 and 1:100 dilutions in
methanol to be used in the spotting solutions. The matrix used was a saturated solution of
α-cyano-4-hydroxycinnamic acid in acetonitrile with 0.1% trifluoroacetic acid. Spotting
solutions were prepared by adding 1 µL of sample to 12 µL of the matrix diluent, and
finally a 12 µl aliquot of the matrix solution was added. A MALDI plate was spotted
with 0.5 µL of this sample for analysis.
II.N. MALDI-TOF analysis of heme samples from DHP
MALDI samples were analyzed in an Applied Biosystems 4700 Proteomics
Analyzer. Analysis was conducted in reflector positive mode.
II.O. Preparation of isotopically labeled heme samples for (LC-MS) analysis
Samples of isotopically labeled heme were obtained individually from purified
samples of DHP. First, 20 µL of a purified DHP sample was transferred to a microfuge
tube. Next, 180 µl of 0.05% acetic acid in acetonitrile was added to denature the protein
and release the heme into solution. The microfuge tube was centrifuged in a tabletop
microfuge for 5 minutes at 14,000 rpm. The supernatant was transferred to a high
performance liquid chromatography (HPLC) glass sample vial and was placed in the
autoloader of a Shimadzu HPLC system equipped with a C18 column from Stellar Phases
Inc., Longhorne, PA 19047. The sample was passed through the system at a flow rate of
1 mL per minute, and the absorbance of eluent was monitored at 398 nm. The mobile
phase used was a 60:40 mix of acetonitrile to water, with a 0.5% acetic acid
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concentration in the final volume. The volume of flow through corresponding to the
largest peak was collected as it eluted between the retention times of 8 and 10 minutes.
These samples were lyophilized to dryness and were frozen at -20 oC.
II.P. LC-MS analysis of purified heme isotopomers
Dried heme samples that had been HPLC purified were taken up in 200 µl of the
HPLC mobile phase mix described previously. The samples were centrifuged briefly with
a tabletop centrifuge and were transferred to Target DP™ Vials C4000-1 (National
Scientific Company). The samples were sealed with 9 MM Blue Caps T/S (Fisherbrand)
and were injected separately into a Hewlett Packard Agilent 1100 series HPLC equipped
with a 5 mM Prevail C-18 column (Alltech). Data was obtained from an LCQ Advantage
Thermo Finnigan coupled with LC-MS and electrospray ionization. The mass range
analyzed was from 350 to 800 daltons, and the flow rate used during analysis was 0.2 ml
per minute.
II.Q. Cloning of the P450 CYP102A2 gene from Bacillus subtilis 168
Cloning procedures were modified from Gustafsson et al.17 Genomic DNA from
Bacillus subtilis (BS) 168 was a gift from the research lab of Dr. Jason Reddick. A
polymerase chain reaction (PCR) was performed using the components and amounts
listed in Table II.1. PCR primers 102A21 and 102A22 contained XbaI and XhoI
restriction sites respectively and are underlined in Table II.1. PCR reactions were
conducted as follows: 1 hold at 98 oC for 4 minutes; 25 cycles of 98 oC for 30 seconds, 60
oC for 30 seconds, and 72 oC for 3 minutes; 72 oC for 5 minutes. PCR product was
confirmed by agarose gel electrophoresis using a 1% agarose gel containing 1 x TAE
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buffer, and was purified by a Qiagen PCR purification kit. Purified PCR product was
stored at -20 oC. The 1 x TAE buffer used in the 1% agarose electrophoresis gel was
obtained by making dilutions of a 50 x TAE buffer stock. 50 x TAE buffer components
included 242.0 g of Tris base, 57.1 mL of glacial acetic acid, and 18.6 g
ethylenediaminetetraacetic acid (EDTA). These components were combined and
dissolved in deionized water. The final volume was brought up to 1 L and the solution
was stored at room temperature.
Table II.1. PCR reaction components and volumes for a single reaction
PCR component Component Volume
Primer 1: 102A21 (5’-CCCTCTAGAGGG
AGGTATGTTCGATGAAGGAAACAAGCC-3’);
Integrated DNA Technologies, Inc.
1 µl
Primer 2: 102A22 (5’-CCCTCGAGTCTT
CTTTATCTATATCCCTGC-3’);
Integrated DNA Technologies, Inc.
1 µl
Template DNA: Genomic DNA from B.S. 168 1 µl
Taq Master Mix;
New England Biolabs
12.5 µl
ddH20 8.5 µl
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Restriction digests were carried out on purified PCR product and the expression
vector, pbluescript II SK(-). Restriction digest components are listed in Table II.2.
Restriction digest reactions were carried out as follows: 1 hold at 37 oC for 2 hours; 1
hold for 65 oC for 20 minutes. Restriction digest products were confirmed by 1% low
melting agarose gel electrophoresis containing 1 x TAE. Vector and PCR product digests
were both purified individually by a Qiagen PCR purification kit. Digest products were
stored at -20 oC.
Table II.2. Restriction digest components and volumes for four separate reactions of
insert, vector, and two controls.
Digest Component Volume
(Vector
Digest)
Volume (PCR
Product)
Volume
(Control#1)
Volume
(Control#2)
1 x NE Buffer 2;
New England Biolabs
2.5 µl 2.5 µl 2.5 µl 2.5 µl
Vector (pbluescript II
SK(-));
Stratagene
6.0 µl None None None
PCR Product (Insert) None 10.0 µl 10.0 µl 10.0 µl
Bovine Serum Albumin
(BSA);
New England Biolabs
0.3 µl 0.3 µl 0.3 µ 0.3 µ
ddH2O 14.2 µl 10.2 µl 10.2 µl 10.2 µl
XbaI restriction enzyme;
Roche
1.0 µl 1.0 µl 1.0 µl None
XhoI restriction enzyme;
New England Biolabs
1.0 µl 1.0 µl none 1.0 µl
40
Purified restriction digest products were used in four, 20µl ligation reactions in an
attempt to generate the desired recombinant plasmid. Reaction components and volumes
are listed in Table II.3. The products of all four reactions were combined and were
successfully transformed into XL1-Blue cells, obtained from Stratagene, and grown on
ampicillin containing Luria Bertani (LB) agar plates. Colonies that grew on the ampicillin
LB plates were then screened in two steps for recombinant DNA containing insert.
Table II.3. Ligation reaction components and volumes for 4 separate reactions
Ligation
Reaction
Components
Component
Volumes
(Reaction #1)
Component
Volumes
(Reaction #2)
Component
Volumes
(Reaction #3)
Component
Volumes
(Reaction #4)
Purified Vector 1 µl 1 µl 1 µl 1 µl
Purified Insert 1 µl 2 µl 3 µl 6 µl
Ligation Buffer;
New England
Biolabs
2 µl 2 µl 2 µl 2 µl
Ligase;
New England
Biolabs
1 µl 1 µl 1 µl 1 µl
ddH2O 15 µl 14 µl 13 µl 10 µl
41
First, several colonies were chosen from the agar plates and were grown
individually overnight in LB media containing ampicillin. Plasmids were purified from
the growth media using a Qiagen plasmid miniprep kit. Purified plasmids were analyzed
on a 1% agarose electrophoresis gel containing 1 x TAE. The sizes of the purified
plasmids were compared to uncut pbluescript II SK(-) vector and uncut CYP102A2-
insert. Bands that were larger than both uncut pbluescript II SK(-) vector and uncut
CYP102A2-insert suggested that ligation of insert into the pbluescript II SK(-) vector was
accomplished.
The second step in screening was to test the successfully ligated plasmids from
the first screen for the presence of ligated insert. This was carried out with PCR using the
components and volumes included in Table II.4. PCR products were analyzed on a 1%
agarose electrophoresis gel including 1 x TAE, and band sizes were compared to cut
CYP102A2-insert. Band sizes that were similar to the cut CYP102A2-insert suggested
that the desired insert had been ligated into the pbluescript II SK(-) vector. Plasmids
containing vector were stored at –80 oC.
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Table II.4. Screening PCR components and volumes for a single reaction
PCR component Component Volume
Primer 1: 102A21 (5’-CCCTCTAGAGGG
AGGTATGTTCGATGAAGGAAACAAGCC-
3’)
1 µl
Primer 2: 102A22 (5’-CCCTCGAGTCTT
CTTTATCTATATCCCTGC-3’)
1 µl
Purified plasmid from a single colony 1 µl
Master Mix;
New England Biolabs
12.5 µl
ddH20 8.5 µl
Large stocks of successfully ligated plasmid containing the CYP102A2 gene were
generated by first transforming the plasmid into HB101 cells. The cells were then plated
on LB containing ampicillin, and incubated at 37 oC overnight. The next day, a single
colony of HB101 cells was picked from the plate and was grown overnight in 25 mL of
ampicillin containing LB as described previously. This overnight culture was used to
isolate the desired plasmid using a Qiagen plasmid miniprep kit. Stocks of the
CYP102A2 plasmid were stored at -80 oC.
II.R. Expression of CYP102A2 in HU227
HU227 cells were transformed with the cloned CYP102A2 plasmid and grew
overnight on a LB agar plate containing ampicillin and unlabeled aminolevulinic acid. A
single colony was selected from the LB plate under sterile conditions using a sterile stick.
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The selected colony was used to inoculate 25 mL of Terrific Broth (TB) in a 50 mL
Falcon tube containing ampicillin and unlabeled aminolevulinic acid. This tube was
placed on its side in a New Brunswick Scientific C24 Incubator Shaker overnight,
shaking at 240 rpm and 37 oC. The next day, 250 µl aliquots of the overnight culture were
used to inoculate 4 separate 2.8 L Fernbach flasks containing 1 L of TB broth each.
Ampicillin trihydrate and unlabeled aminolevulinic acid had been added to each flask of
TB in the amounts and conditions previously stated. Each liter of inoculated broth was
covered with aluminum foil, placed on a New Brunswick Scientific Gio Gyrotory Shaker,
and incubated at room temperature with shaking at 207 rpm. Shaking continued until a 1
mL aliquot of culture had an A600 equal to 2.0. Isopropyl β-D-1-thiogalactopyranoside
(IPTG) was added (0.15 g/L) to initiate overexpression, and shaking continued at 70 rpm.
Cultures were tested for expression of CYP102A2 using electronic absorption
spectrophotometry of the CO-reduced vs reduced heme. Cells were then harvested from
cultures displaying expression.
II.S. Harvest and purification of CYP102A2
Cell cultures testing positive for CYP102A2 over-expression were transferred to
500 mL centrifuge tubes. The cultures centrifuged in a Beckman Avanti J-25 centrifuge
at 9,500 rpm at 4 oC for 30 minutes using a JLA 10 Beckman rotor. The supernatant was
discarded, and the pellet was resuspended and homogenized in 100 mL of pH 7.4, 50 mM
phosphate equilibration buffer containing 15% glycerol. Cell walls were lysed with
lysozyme for 30 minutes at room temperature while stirring. The lysed cells were then
transferred to 25 mL centrifuge tubes and the membranes were degraded by sonication
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using a Fisher Scientific 60 Sonic Dismembrator in four 30-second bursts at a power of
13W while on ice. The 25 mL centrifuge tubes were then transferred to a JA-20 Beckman
rotor and centrifuged at 19,000 rpm for 30 minutes at 4 oC. Supernatant containing the
CYP102A2 was decanted and saved. The cell fragments were discarded. CYP102A2
concentration was determined by UV-Vis spectrophotometry of the CO-reduced vs
reduced heme.
Next, the crude CYP102A2 was applied to a purification column containing
Whatman pre-swollen DE52 diethylaminoethyl cellulose anion exchange that had been
equilibrated previously using about 5 column volumes of 50 mM phosphate buffer at pH
7.5 containing 15% glycerol. The extract was passed through the purification column in a
chromatography refrigerator at 4 oC, and CYP102A2 remained on the column. The
protein was eluted using an increasing concentration gradient of 50mM to 200mM NaCl
in equilibration buffer. Flow through was collected in five 50 mL fractions and were
tested for the presence of CYP102A2 using UV-Vis spectroscopy of the CO-reduced vs
reduced heme of CYP102A2.
Fractions containing CYP102A2 were diluted with equilibration buffer to lower
the NaCl concentrations in each to less than 20 mM. These dilutions were run through a
fast flow Q-sepharose (GE Healthcare) column to apply the CYP102A2. This column had
been pre-equilibrated with about 5 column volumes of 50 mM phosphate buffer at pH 7.5
containing 15% glycerol. Protein was eluted using an increasing concentration gradient of
phosphate buffer from 100 to 300 mM at pH 7.4 with 15% glycerol. Flow through was
collected in five 50 mL fractions. Fractions collected from the Q-sepharose column were
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tested by spectrophotometry without further treatment using a Varian CARY 100 Bio
UV-Visible Spectrophotometer. A quartz cuvette was filled with deionized water and a
baseline was recorded from 250 nm to 500 nm. The water filled cuvette was then moved
to the reference cell compartment, and a second quartz cuvette was used in the sample
cell compartment to test the protein fractions collected from the size exclusion column.
The samples were scanned from 250 nm to 500 nm in baseline subtraction mode.
Fractions that displayed an absorbance ratio of 2:1, at 280 nm and 418 nm respectively
were saved.
The pure fractions were diluted with 15% glycerol to lower the phosphate
concentration to no more than 50 mM in each fraction. The dilutions were run through a
short column of Whatman pre-swollen DE52 diethylaminoethyl cellulose anion exchange
that had been equilibrated with pH 7.4 equilibration buffer. The applied CYP102A2 was
eluted all at once as a tight, red band using 250 mM phosphate buffer at pH 7.4 and 100
mM NaCl with 15% glycerol. The purified protein was tested for CYP102A2
concentration using UV-Vis spectrophotometry of the CO-reduced heme of CYP102A2.
The purified samples were then frozen at -80 oC.
II.T. CYP102A2 assay via UV-Vis spectrophotometry of the CO-reduced heme
The concentration of CYP102A2 in Hu227 cells was found using a variation of
the method described by Omura and Sato 22 for detection of the hemoprotein, cytochrome
P450. The extinction coefficient was assumed to be ε450= 91 mM-1 cm-1, and the
concentration of CYP102A2 was determined from the spectra of the reduced CO vs
reduced heme complexes.17
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The CYP102A2 concentration in intact cells was determined by centrifuging a 2
mL aliquot of cultured cells from the Fernbach flask in a Fisher Scientific Centrific
Centrifuge spinning at full speed for 10 minutes at 4 oC. The growth broth was discarded
by decanting, and the cell pellet was resuspended in 2 mL of 50 mM phosphate buffer at
pH 7.4 containing 15% glycerol. Next, 5 mg of sodium dithionite (Sigma) was dissolved
in the 2 ml cell suspension to reduce the prosthetic heme iron of CYP102A2. One quartz
cuvette was filled with 1 ml of the reduced cells and placed in the sample compartment of
a Varian CARY 100 Bio UV-Visible Spectrophotometer. A baseline spectrum was
recorded on the cells from 400 nm to 500 nm, and this cuvette was placed into the
reference compartment of the spectrophotometer. A second cuvette was filled with the
remaining 1 mL of reduced cells, and carbon monoxide gas was gently bubbled through
the cell suspension for one minute to form the reduced CO complex. This cuvette was
placed in the sample compartment, and the absorbance spectrum of the reduced vs
reduced CO complex of CYP102A2 was recorded from 400 nm to 500 nm with the
baseline subtracted. The reduced CO complex of CYP102A2 absorbed at 450 nm.
The CYP102A2 concentration in crude, cell-free extract was determined by
diluting a 200 µL aliquot of the extract up to 2 mL with 50 mM phosphate buffer at pH
7.4 containing 15% glycerol. These 2 mL were divided between 2 quartz cuvettes. Next,
a few grains of sodium dithionite were added, and a baseline spectrum was taken on 1 ml
of the sample from 400 nm to 500 nm. Afterwards, that sample was moved to the
reference compartment of the spectrophotometer. The remaining 1 ml of cells was gently
bubbled with carbon monoxide for 1 minute, and a few grains of sodium dithionite were
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added to form the reduced CO complex. This cuvette was placed in the sample
compartment of the spectrophotometer, and the spectrum of the reduced vs reduced CO
complex was taken with baseline subtraction. The procedure for finding the concentration
of CYP102A2 in concentrated, purified samples was identical to that of the crude extract
except that a 20 µL aliquot of purified sample was diluted up to 2 mL in this assay.
II.U. Activity assay of CYP102A2 with 12-p-nitrophenoxycarboxylic acid
The activity of the purified CYP102A2 was tested for 12-p-
nitrophenoxycarboxylic acid (pNCA) as substrate by monitoring formation of the product
p-nitrophenolate at 410 nm. The procedure was modified from that of Schwaneberg et
al.18 A quartz cuvette was filled with 7.5 µL of 6 mM pNCA in DMSO. Next, 0.1 nmol of
CYP102A2 was added to the cuvette, and enough 0.1M Tris-HCl buffer at pH 8.2 was
added to bring the solution up to a final volume of 1 mL. The cuvette was placed into the
sample cell of a Varian CARY 100 Bio UV-Visible Spectrophotometer, and the blank
spectrum was taken to zero the instrument. Next, 100 µL of 1mM NADPH was added to
initiate the reaction. The absorbance at 410 nm was recorded every 2 seconds until there
was no longer a change absorbance. A negative control spectrum was also taken for 200
seconds, where the reaction was never initiated by the addition of NADPH.
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CHAPTER III
RESULTS AND DISCUSSION
III.A. Synthesis of 13C and 15N δ-aminolevulinic acid (ALA) isotopomers
The procedure for synthesizing the three isotopomers of aminolevulinic acid
(ALA) that we selected was that of Wang and Scott10. This allowed for the production of
[4-13C] ALA, [5-13C] ALA, and [15N] ALA in a straight forward manner using four
separate chemical steps. The synthesis of the phthalimidolevulinic acid ethyl ester was
the key step in the procedure and required an extra amount of care to insure that any
moisture was eliminated from the reaction. The overall yield for the most productive
workup of ALA conducted was 67%, and the reported yield from the literature was 90%.
Prior to working with the isotopically labeled derivatives of glycine, the total synthesis
was performed starting from unlabeled glycine. This was done in order to refine the
synthetic techniques without wasting large amounts of the much more expensive
isotopomers of glycine. The amount of starting material was experimented with as well,
where starting masses of glycine were either 0.5 g (6.7 mmol) or 1.0 g (13.3 mmol). Both
starting masses were successfully worked up to the final product ALA, but the larger
amount of starting material provided the most efficient synthesis.
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Figure III.1. Synthesis of phthalylglycine from phthalic anhydride and glycine, with the
numbering scheme shown.
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The formation of phthalylglycine was the first step in the synthesis, and the yield
was near 90% in all attempts. This was relatively close to the reported yield of 98% from
the literature. [1-13C] glycine was used in the synthesis of [1-13C] phthalylglycine, [2-13C]
glycine was used in the synthesis of [2-13C] phthalylglycine, and [15N] glycine was used
in the synthesis of [15N] phthalylglycine. Characterization of the products in each
synthesis was achieved with 1H-NMR spectroscopy. NMR data are displayed in Table
III.1, and compared to the given literature values and chemical shift assignments. The 1H-
NMR experimental chemical shift and coupling constant values for [1-13C]
phthalylglycine were in agreement with the available reference values.10
The assigned chemical shifts of [2-13C] phthalylglycine and [15N] phthalylglycine
were identical to those of [1-13C] phthalylglycine. This was expected because the 13C and
15N isotopes should not affect the distribution of electrons in the molecules. Additionally,
the large J coupling constant value observed in the [2-13C] phthalylglycine 1H-NMR data
was indicative of hydrogens being split directly by a 13C through a single bond. This
degree of splitting strongly suggested, that there was a 13C isotope incorporated at
position two in phthalylglycine (Figure III.1)
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[15N] phthalylglycine sample displayed no splitting patterns in the 1H-NMR
spectrum with respect to the two hydrogens located at carbon 2 of the phthalylglycine
structure. However, this reaction does not lend itself to the loss or replacement of a
nitrogen atom, and it can be assumed that the 15N was incorporated into the product. The
[15N] phthalylglycine sample shared identical chemical shifts with those of [1-13C]
phthalylglycine. These similar chemical shifts suggest that the connectivity of the 15N
labeled product is consistent with phthalylglycine.
Table III.1. 1H-NMR data for the synthesized isotopomers of phthalylglycine, the
available literature values, and chemical shift assignments.
Experimental (1H-
NMR, ppm); (J, Hz)
Literature10 Assignment
[1-13C] phthalylglycine 2.47
4.28 (2J = 5.7)
7.88
4.40 (J = 5.4)
7.82
m, DMSO (solvent)
d, 2H, CH2
13CO
AA’BB’, 4H, H-Ph
[2-13C] phthalylglycine 2.47
4.28 (1J = 141.8)
7.88
m, DMSO (solvent)
d, 2H, 13CH2CO
AA’BB’, 4H, H-Ph
[15N] phthalylglycine 2.47
4.28
7.88
m, DMSO (solvent)
d, 2H, 15NCH2CO
AA’BB’, 4H, H-Ph
Figure III.2. Synthesis of phthalimidoacetyl chloride from phthalylglycine and thionyl
chloride, with the numbering scheme shown.
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The second step in the synthesis of ALA was the preparation of the
phthalimidoacetyl chloride isotopomers. Extra care was taken to ensure that the reactant
phthalylglycine was completely dry. Any moisture in the reaction with thionyl chloride
would convert the acid chloride back to a carboxylic acid. Product yields of
phthalimidoacetyl chloride isotopomers were near 98% in most attempts. Experimental
1H-NMR data are compared to the available reference values, with the corresponding
chemical shift assignments in Table III.2. The experimental chemical shift and J coupling
constant values of [1-13C] phthalimidoacetyl chloride were in good agreement with the
literature values.10 The chemical shifts of synthesized [2-13C] phthalimidoacetyl chloride
and [15N] phthalimidoacetyl chloride were identical to those of [1-13C] phthalimidoacetyl
chloride. This suggested that each of the isotopomers possessed the desired connectivity
corresponding to phthalimidoacetyl chloride.
The large J coupling constant associated with the chemical shift of 4.82 ppm in
the data of [2-13C] phthalimidoacetyl chloride suggested the presence of a 13C atom
incorporated into the two position of the phthalimidoacetyl chloride structure seen in
Figure III.3. In this position, the attached hydrogens were split directly by 13C through a
single bond.
The chemical shifts corresponding to the hydrogens located at the two position
were not split in the [15N] phthalimidoacetyl chloride 1H-NMR data. However, the
presence of the chemical shift at 7.85 ppm demonstrated the conservation of the
protecting group in the preceding reaction, and therefore the protected 15N atom must
have also been retained.
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Table III.2. 1H-NMR data for the synthesized isotopomers of phthalimidoacetyl chloride,
the available literature values, and chemical shift assignments.
Experimental (1H-
NMR, ppm); (J, Hz)
Literature10 Assignment
[1-13C] phthalimidoacetyl
chloride
4.82 (2J = 5.8)
7.25
7.85
4.80 (2J = 5.8)
7.78
d, 2H, CH2
13CO
s, CDCl3 (solvent)
AA’BB’, 4H, H-Ph
[2-13C] phthalimidoacetyl
chloride
4.82 (1J = 146.3)
7.25
7.85
d, 2H, 13CH2CO
s, CDCl3 (solvent)
AA’BB’, 4H, H-Ph
[15N] phthalimidoacetyl
chloride
4.82
7.26
7.85
s, 2H, 15NCH2CO
s, CDCl3 (solvent)
AA’BB’, 4H, H-Ph
Figure III.3. Synthesis of phthalimidolevulinic acid ethyl ester from the coupling
reaction of phthalimidoacetyl chloride and zinc homoenolate, with the numbering scheme
shown.
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The third synthetic step was the key step in the synthesis of ALA.10 This was the
most labor intensive of the four steps in the synthesis. It was also imperative that reagents
involved with this step were kept dry at all times as this was required for the formation of
the zinc homoenolate. This step usually proceeded without incident, but in the cases
where NMR data showed that products were not formed it was difficult to determine
what had gone wrong. We soon learned to take every precaution possible to ensure that
reagents were dry and always reacting under nitrogen gas.
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The yield of phthalimidolevulinic acid ethyl ester from phthalimidoacetyl
chloride was 90% in the most efficient synthesis conducted. This relatively high yield
was in agreement with literature values for acylation reactions of homoenolate in the
presence of a palladium catalyst (93%). 1H-NMR data from the [4-13C]-
phthalimidolevulinic acid ethyl ester were in close agreement with the literature values.
The spectral data are shown in Table III.3.
Chemical shifts in all of the isotopomers synthesized in this step were very
similar, suggesting a connectivity that is consistent with phthalimidolevulinic acid ethyl
ester. The 1H-NMR data of the [5-13C] phthalimidolevulinic acid ethyl ester showed
splitting, with a large J coupling constant of 193.3 Hz, that was centered at the chemical
shift 4.55 ppm. This chemical shift corresponded to the two hydrogens on the carbon five
position. This large J value suggested that 13C was present at the five position of the
molecule, and that it was splitting the hydrogens directly connected through a single
bond. No splitting was observed with respect to the hydrogens at the five position in [15N]
phthalimidolevulinic acid ethyl ester. The presence of the protecting group was evident
however, as was shown by the multiplet at 7.80 ppm, and its presence suggested that the
15N atom had been retained.
A key structural aspect of the phthalimidolevulinic acid ethyl ester was observed
in the 1H-NMR data of all of the isotopomers. The five protons of the ethyl ester group
displayed chemical shifts at roughly 1.25 ppm as a triplet and 4.14 ppm as a quartet. The
four protons on carbons two and three were also evident in all of the isotopomers. The
chemical shift of the protons on carbon three was observed as a quartet between 2.74 and
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2.85 in all of the isotopomers except for [4-13C] phthalimidolevulinic acid ethyl ester.
Here the peak was further split into a multiplet by the neighboring 13C atom. The protons
of carbon two were also split into a multiplet by the nearby 13C atom of [4-13C]
phthalimidolevulinic acid ethyl ester and were centered at 2.65 ppm. These protons were
also seen at the same chemical shift in the 1H-NMR of the other two isotopomers, but
they existed as triplets due to the lack of another nearby atom with a nuclear spin I = ½.
Table III.3. 1H-NMR data for the synthesized isotopomers of phthalimidolevulinic acid
ethyl ester, the available literature values, and chemical shift assignments.
Experimental (1H-
NMR, ppm); (J, Hz)
Literature 10 Assignment
[4-13C]
phthalimidolevulinic acid
ethyl ester
1.24 (3J = 7.2)
2.65
2.74
4.13 (3J = 7.2)
4.55 (2J = 4.0)
7.25
7.80
1.26 (3J = 7.2)
2.65
2.84
4.14 (3J = 7.2)
4.56 (2J = 4.0)
7.80
t, 3H, CH2CH3
m, 2H, 13COCH2CH2
m, 2H, 13COCH2CH2
q, 2H, OCH2CH3
d, 2H, NCH2
13CO
s, CDCl3 (solvent)
AA’BB’, 4H, H-Ph
[5-13C]
phthalimidolevulinic acid
ethyl ester
1.25 (3J = 7.4)
2.65 (3J = 6.7)
2.84 (3J = 6.4)
4.14 (3J = 7.3)
4.55 (1J = 193.3)
7.25
7.80
t, 3H, CH2CH3
t, 2H, COCH2CH2
t, 2H, COCH2CH2
q, 2H, OCH2CH3
d, 2H, N13CH2CO
s, CDCl3 (solvent)
AA’BB’, 4H, H-Ph
[15N] phthalimidoacetyl
chloride
1.25 (3J = 7.4)
2.65 (3J = 6.9)
2.85 (3J = 6.9)
4.14 (3J = 6.9)
4.55
7.25
7.80
t, 3H, CH2CH3
t, 2H, COCH2CH2
t, 2H, COCH2CH2
q, 2H, OCH2CH3 s,
s, 2H, 15NCH2CO
CDCl3 (solvent)
AA’BB’, 4H, H-Ph
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Figure III.4. Synthesis of aminolevulinic acid from the acid hydrolysis of
phthalimidolevulinic acid ethyl ester, with the numbering scheme shown.
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The final reaction in the synthesis of aminolevulinic acid (ALA) was the acid
hydrolysis and deprotection of the phthalimidolevulinic acid ethyl ester. Product yield
was close to 90% in most attempts. The yield for the overall synthesis was 67% in the
most efficient synthesis conducted. This was accomplished by beginning with 1.01 grams
(13.28 mmol) of the starting material glycine, yielding 1.51 grams (8.92 mmol) of
aminolevulinic acid after the completion of the four synthetic steps. Recrystalization of
the ALA from ethanol and ether provided sufficiently pure product for the growth of E.
coli HU227. This was also a cost effective method of obtaining the ALA isotopomers.
1H-NMR data for [4-13C] ALA and [15N] ALA agreed well with the literature
values, and all data are shown in Table III.4. The chemical shifts in all experimental 1H-
NMR are slightly lower than the literature values that were available by about 0.2 ppm in
each case, but these small upfield shifts are observed in all of the chemical shifts. This
may be due to a bad reference lock in the solvent D2O, as the solvent used for each NMR
sample came from the same source. Despite this small discrepancy, the J coupling
constants are very similar to the literature values in general, and are indicative of the
structure of aminolevulinic acid.
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The peak of the chemical shift at 2.76 ppm in the [4-13C] ALA sample, which
corresponds to the protons of carbon three, was split into a distinct multiplet. This
suggests that the incorporation of a 13C label in the four position of ALA has been
accomplished. If there were no 13C nearby this position, as in the [15N] ALA sample, the
protons of carbon three would only be expected to split into a triplet. This is indeed what
is seen in the [15N] ALA sample at 2.73 ppm. Interestingly, the [5-13C] ALA sample
showed a much less distinct multiplet character. This indicated that the 13C atom at the
five position of [5-13C] ALA was splitting the protons at the three position to a minor
extent. A similar effect was seen in the chemical shift at 2.55 ppm of [4-13C] ALA, where
the protons that were three bonds away were also split into a slight multiplet by the 13C
atom in the four position of the molecule. These particular protons, in position two of the
molecule, were left unaffected by the 13C atom of [5-13C] ALA as it was too far away. In
this case, these protons were merely split by their neighboring protons into a triplet. The
same characteristic was seen in [15N] ALA.
The chemical shift at 3.97 ppm of the [4-13C] ALA sample suggested that the 13C
atom was in the four position, as it was able to significantly split its neighboring protons
into a doublet with a J coupling constant of 4.2 Hz. These same protons were even more
significantly split (J = 143.3) in the [5-13C] ALA sample, which suggested that these
protons were directly bonded with the 13C atom. This provided significant evidence that a
13C atom was incorporated at the five position of the molecule.
Finally, no chemical shifts were split due to the 15N atom in the [15N] ALA
sample. Even though this left us without a method of positively identifying the presence
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of a 15N atom in the molecule, we were reasonably sure of its presence. The high level of
purity in the synthetic starting material [15N] glycine, and the fact that none of the
reactions carried out in the synthesis lended themselves to the loss of a nitrogen atom was
enough to assure us that the 15N atom was incorporated. Additionally, the group that
originally devised this method of ALA synthesis reported that they successfully
generated [15N] ALA using this method. Furthermore, our [15N] ALA 1H-NMR data
matched well with what had been reported previously.10, 28
Table III.4. 1H-NMR data for the synthesized isotopomers of aminolevulinic acid, the
available literature values, and chemical shift assignments.
Experimental (1H-
NMR, ppm); (J,
Hz)
Literature 10, 28 Assignment
[4-13C] aminolevulinic
acid
2.55
2.76
3.97 (2J = 4.2)
2.71
2.90
4.13 (2J = 3.9)
m, 2H, 13COCH2CH2
m, 2H, 13COCH2CH2
d, 2H, NCH2
13CO
[5-13C] aminolevulinic
acid
2.53 (3J = 6.2)
2.73
3.95 (1J = 143.3)
t, 2H, COCH2CH2
m, 2H, COCH2CH2
d, 2H, N13CH2CO
[15N] aminolevulinic acid 2.52 (2J = 6.9)
2.71 (2J = 6.1)
3.95
2.60 (2J = 6.3)
2.78 (2J = 6.3)
4.01
t, 2H, COCH2CH2
t, 2H, COCH2CH2
s, 2H, 15NCH2CO
The method for the synthesis of isotopomers of aminolevulinic acid, developed by
Wang and Scott10, was relatively simple and cost effective for our purposes. However, we
were not able to achieve the high overall yield of 90% that they originally reported.
Monitoring the formation of our product with 1H-NMR also seemed to be logical and
productive. That is because changes in the chemical shifts, going from reactants to
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products in each synthetic step, were significant enough to make 1H-NMR a valuable tool
for the characterization of our isotopomers.
III.B. Expression and purification of dehaloperoxidase
For reasons discussed previously, dehaloperoxidase (DHP) was chosen as a
representative heme protein for 13C and 15N incorporation. Our expression system
consisted of a DHP encoding plasmid transformed into the E. coli Hu227 cells, where
gene expression was under the control of a lac promoter. The synthesized isotopomers of
aminolevulinic acid (ALA) were required for the cells to survive as they were incapable
of generating the ALA on their own. This ensured the incorporation of 13C and 15N labels
as the cells synthesized the heme for DHP because their only supply of the heme
precursor was the isotopomer of ALA in the growth media.
DHP was successfully overexpressed and purified from E. coli HU227 cells
grown in Luria Bertani growth media containing the synthesized isotopomers of
aminolevulinic acid. A typical absolute absorbance spectrum of the CO-reduced heme
complex of purified DHP is displayed in Figure III.5. It can be seen that the λ-max was
approximately 423 nm. Spectra of the CO-reduced heme complex of DHP in the whole
cells displayed a λ-max at 420 nm with an absorption of about 0.030 in cultures
displaying good expression. Typical yields of DHP were moderate after purification, and
were between 91.5 and 189 nmoles of protein per liter of growth media.
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Figure III.5. Absolute absorbance spectrum of the CO-reduced heme complex of
purified dehaloperoxidase.
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III.C. MALDI-TOF and LC-MS analysis of isotopically labeled heme from
dehaloperoxidase
Matrix-assisted laser desorption/ionization-time of flight mass spectrometry
(MALDI-TOF) was conducted on heme isotopomers that had been extracted and purified
from dehaloperoxidase. Unlabeled heme from DHP that was overexpressed with
unlabeled aminolevulinic acid (ALA), and labeled heme from DHP that was
overexpressed with [5-13C] ALA are shown in Figures III.6 and III.7 respectively.
Neither the [4-13C] ALA or [15N] ALA gave MALDI-TOF spectra that could be
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interpreted. It is likely that the samples were either too impure, or had degraded prior to
analysis.
When comparing the MALDI-TOF spectrum of the unlabeled heme sample
(Figure III.6) to the labeled heme sample (Figure III.7), an increase of 8 amu was
observed in the major peak of interest. The mass increase from 616 m/Z to 624 m/Z
suggests that eight 13C atoms were successfully incorporated into the heme
biosynthetically, as was predicted. Presently, we have not been able to characterize the
second major peak in each of the MALDI-TOF figures. If these peaks were due to a heme
dimer complex of some kind, a coordinating molecule would need to present to stabilize
the structure. However, the difference in m/Z between the major peaks in Figure III.6 is
not equal to the difference in m/Z between the two peaks in Figure III.7. This eliminates
the possibility of a single type of molecule coordinating such a heme complex in both of
the MALDI-TOF spectra. It is more likely that these secondary peaks are due to
contamination or impurities of the heme samples, given that these samples were not
purified extensively.
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Figure III.6. MALDI-TOF spectrum of unlabeled heme from DHP, displaying a major
peak at m/Z value of 616.
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Figure III.7. MALDI spectrum of 13C labeled heme from DHP grown in [5-13C] ALA,
displaying a major peak at m/Z value of 624.
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After the failure to generate significantly pure MALDI-TOF samples of the
biosynthetically labeled heme, we decided to try a different approach. Other researchers
have shown that it is possible to separate and identify the mass of tert-butyl 1-methyl-2-
propynyl ether adducted hemes (705 Da) in a protein sample using high performance
liquid chromatography-mass spectrometry with electrospray ionization (LC-MS).29 Under
similar conditions, attempts were made to analyze HPLC purified, isotopically labeled
heme samples with LC-MS. The LC-MS chromatograms of the three isotopomers of
heme are displayed in Figure III.8. All three samples displayed remarkably similar
retention times and resolution. The labeled heme was eluted at about 29 minutes in each
624.22
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run. It can also be seen in the chromatogram that there are large peaks flanking the 29
minute elution peak. Although we were not able to characterize the contents of these
peaks, it is likely that these are protein fragments that were dissolved in the sample, and
were not well separated from the heme in the reverse phase column of the HPLC prior to
LC-MS analysis. The amount of impurities relative to the heme analyte provides some
insight into the level of purity in the MALDI-TOF samples discussed earlier. In these
samples, heme was merely purified in a short C18 sep-pak column, so the level of purity
would have been greatly reduced. Upon realizing this, it is reasonable that some of our
MALDI-TOF samples were not viable. The exact masses of each heme sample,
corresponding to the heme elution times of the LC-MS chromatograms, are shown in
Figures III.9, III.10, and III.11.
The masses of heme synthesized biosynthetically from [4-13C] ALA and [5-13C]
ALA are shown in Figures III.9 and III.10 respectively. Both samples displayed a major
peak at 624.2 m/Z. This is consistent with the expected mass for these isotopomers, and
suggests that the incorporation of eight 13C atoms into the prosthetic heme was successful
as was indicated previously in the MALDI-TOF data for [5-13C] ALA.
There are also two additional major peak in each of the three figures
corresponding to the exact masses. These two major peaks are of identical mass in each
sample, and therefore are not related to the heme itself. These peaks are probably
representative of impurities in the samples, as they were each prepared in the sample
manner.
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The mass of heme synthesized biosynthetically from [15N] ALA is shown in
Figure III.11. The major peak at 620.2 m/Z is also consistent with the expected mass for
this isotopomer, and suggests that four 15N atoms were successfully incorporated into the
heme. This is significant because the biosynthesis of 15N labeled heme via this route has
not been previously described.
Figure III.8. LC-MS chromatogram of purified isotopically labeled heme from DHP.
(a.) Heme purified from DHP overexpressed in [4-13C] ALA. (b.) Heme purified from
DHP overexpressed in [5-13C] ALA. (c.) Heme purified from DHP overexpressed in
[15N] ALA. (*) marks the peak corresponding to elution of heme.
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Figure III.9. Exact masses of components contained in the peak corresponding to the
elution of heme in chromatogram (a) of Figure III.8 containing heme purified from DHP
overexpressed in [4-13C] ALA.
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Figure III.10. Exact masses of components contained in the peak corresponding to the
elution of heme in chromatogram (b) of Figure III.8 containing heme purified from DHP
overexpressed in [5-13C] ALA.
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Figure III.11. Exact masses of components contained in the peak corresponding to the
elution of heme in chromatogram (c) of Figure III.8 containing heme purified from DHP
overexpressed in [15N] ALA.
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III.D. Cloning of the CYP102A2 gene of Bacillus Subtilis 168
One of the goals in this project was to generate a recombinant plasmid containing
an expression vector and the CYP102A2 gene. The long-term goal of this project is to be
able to use this recombinant plasmid in the 13C- and 15N-heme incorporating expression
system. The current system for production of P450 BM3 in this lab involves a plasmid
containing a T7 promoter for control of expression.30, 31 E. coli Hu227 cells do not
contain the gene that expresses the T7 polymerase, so these plasmids would not be
expressed in Hu227 cells without first transfecting the cells with the DNA that would
allow T7 polymerase expression.
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Our first attempt at solving this expression problem was to utilize a two-plasmid
system. The goal was to transform the Hu227cells with a plasmid that encoded for the T7
polymerase and imparted kanamycin resistance, and then transform with a second
plasmid that encoded for the P450. Problems arose with this system because of the
difficulty in transforming Hu227. This strain of cells is difficult to make competent in
order to perform the transformations. Furthermore, once both plasmids were finally
transformed into the cells, no expression was ever observed after induction with IPTG.
This 2-plasmid expression system was soon abandoned after generating the transfected
cells.
We have been able to generate a recombinant plasmid containing an expression
vector under the control of a lac promoter, and the CYP102A2 gene. This was
accomplished using a method modified from Gustafsson et al.17 The first step was to
amplify the CYP102A2 gene from genomic Bacillus subtilis 168 DNA. A polymerase
chain reaction (PCR) was used to accomplish this, and the PCR product was confirmed
by agarose gel electrophoresis, shown in Figure III.12. It can be seen in lanes 1 and 2
containing the PCR product, that the size of the fragment is near 3183 base pairs, which
is the size of the CYP102A2 gene according to the published sequence listed by the
Bacillus subtilis data bank.
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Figure III.12. 1% Agarose electrophoresis gel containing polymerase chain reaction
products. Lanes 1 and 2 both contain PCR product containing CYP102A2 gene.
The next step was to cut both the expression vector and PCR product in order to
generate complementary ends on each. This would allow the vector and PCR product to
be ligated together in a subsequent step. The primers used in the PCR reaction in the
previous step inserted two restriction sites, which flanked the CYP102A2 gene. An XbaI
restriction site was cloned outside the 5’ end of the CYP102A2 coding region, and an
XhoI restriction site was cloned outside the 3’ end of the coding region. These restriction
sites in the PCR product were cut in this step, as were these same sites in the multicloning
region of the pbluescript II SK(-) vector.
Controls were also conducted in the restriction digest steps in order to ensure that
both restriction enzymes were functioning properly. The results of all restriction digests
are seen in the agarose gel in Figure III.13. Lanes 1 and 2 of the gel show the cut PCR
product and expression vector respectively. It is apparent that these two fragments are
similar in size, which is predicted based on the expected size of the PCR product versus
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the linear plasmid. Lanes 3 and 4 show the results of the control experiments where one
restriction enzyme was omitted in each reaction. These controls showed that the
restriction enzymes were both active. If one of the enzymes had not cut the vector
substrate, the bands in lanes 3 and 4 would not both be similar in size to the cut vector in
lane 2.
Figure III.13. 1% Agarose electrophoresis gel containing restriction digest products.
Lane 1 contains digest of the CYP102A2 gene from the PCR. Lane 2 contains digest of
pbluescript II SK(-) vector. Lane 3 contains digest of vector with restriction enzyme XhoI
in the absence of XbaI. Lane 4 contains digest of vector with restriction enzyme XbaI in
the absence of XhoI.
The cut PCR product and vector were then included in ligation reactions.
However, the ligation products needed to be screened for the presence of both the
CYP102A2 gene and the expression vector. This was accomplished in two screening
procedures. In the first screen the ligation product was transformed into XL1-Blue cells,
and they were grown on agar plates containing ampicillin. Any colonies that grew on the
plates were known to at least contain the expression vector. This was because the
expression vector is what provided the cells with ampicillin resistance. Individual
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colonies of the transformed cells were grown overnight to produce large amounts of the
plasmid, which were isolated from each culture the next day. The purified plasmids were
passed through an agarose gel for analysis (Fig III.14), and any plasmids that were nearly
twice the size of cut PCR product or cut expression vector were saved. These were the
most likely candidates to contain the expression vector with the P450 gene incorporated.
It can be seen that the plasmid in lane three of Figure III.14 was the most likely candidate
out of the 7 plasmids shown in the gel, since it appears to be nearly twice the size of the
native vector.
Figure III.14. 1% Agarose electrophoresis gel containing purified plasmids from XL1-
Blue cells transformed with ligation products. Lane 1 contains undigested pbluescript II
SK(-) vector. Lane 2 contains undigested CYP102A2 gene from PCR. Lanes 3 through 9
contain purified plasmids from individual colonies of transformed XL1-Blue cells.
Good candidates from the first screening step were taken on to the second screen.
This screen was accomplished by PCR, using the 102A21 and 102A22 primers on the
individual purified plasmid samples. The PCR products were analyzed by 1% agarose gel
electrophoresis (Fig III.15), and the band sizes were compared to cut CYP102A2-insert.
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The band sizes that were close in size to the CYP102A2-insert suggested that the desired
DNA fragment had been ligated into the pbluescript II SK(-) vector.
Figure III.15. 1% Agarose electrophoresis gel containing PCR products of purified
plasmids from XL1-Blue cells transformed with ligation products. Lane 1 contains the
negative control PCR product of non-recombinant pbluescript II SK(-) vector. Lane 2
contains undigested CYP102A2 gene from PCR. Lanes 3 through 9 contain PCR
products of the purified plasmids from individual colonies of transformed XL1-Blue cells
shown in Fig.5.
III.E. Expression and purification of CYP102A2
CYP102A2 was successfully overexpressed and purified from E. coli HU227
cells grown in Terrific Broth growth media containing the unlabeled aminolevulinic acid
(ALA) (Acrōs). A typical absorbance spectrum of the reduced heme versus CO-reduced
heme complex of CYP102A2 in whole cells is displayed in Figure III.16. The strong
heme absorbance at 450 nm associated with P450 enzymes makes it possible to track
expression of P450 enzymes in whole cells by difference spectrophotometry. This is very
useful in determining whether to harvest cells based on their expression. Typical yields of
CYP102A2 were much lower than those seen in dehaloperoxidase after purification, and
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were about 4 nmoles of protein per liter of growth media. The purified CYP102A2 was
passed through a sodium dodecyl sulfate-polyacrylamide gel shown in lane six of Figure
III.17. Two bands were observed, where one band at about 119 kilodaltons was
expected.26 Our data suggest that there was some level of degradation in the sample.
Despite the low yields displayed by CYP102A2, we have shown that it is possible to
generate this protein in our expression system with unlabeled ALA; and therefore, it
should be possible to isotopically label the prosthetic heme of CYP102A2
biosynthetically using isotopomers of ALA, particularly with improved purification
strategies. However, more experiments should be conducted to optimize the growth
conditions of the protein with unlabeled ALA, in order to make labeling experiments cost
effective.
Figure III.16. Absorbance spectrum of reduced vs CO-reduced heme complex of
CYP102A2 in whole cells.
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Figure III.17. SDS-PAGE gel; lane 1 = molecular weight marker, lane 2 = purified DHP
grown with [4-13C] ALA, lane 3 = purified DHP grown with [5-13C] ALA, lane 4 =
purified DHP grown with [15N] ALA, lane 5 = purified DHP stock with unlabeled heme,
lane 6 = purified CYP102A2.
III.F. Activity assay of CYP102A2 with 12-p-nitrophenoxycarboxylic acid
The ability of purified CYP102A2 to catalyze the hydroxylation of 12-p-
nitrophenoxycarboxylic acid (pNCA) and generate the product p-nitrophenolate was
studied, and rates were compared to similar studies conducted with the P450 BM-3 and
BM-3 F87A mutant. The rate of catalysis in CYP102A2 was much less than both
reported values for the wild-type P450 BM-3 and the BM-3 F87A mutant. Control
experiments, where the electron donor NADPH was not added, showed no enzymatic
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activity over 200 seconds. Reduced activity compared to the P450 BM-3 and BM-3 F87A
may suggest that the active site of CYP102A2 does not accommodate saturated, medium
chain, unbranched fatty acids well. It should also be noted that, in another study17,
catalytic rates were generally higher in unsaturated and branched chain fatty acids. It is
also possible that the reduced catalytic activity is due to protein degradation. The sodium
dodecyl sulfate-polyacrylamide gel in Figure III.17 shows two bands in lane six, where a
single band at around 119 kilodaltons was expected. Although further studies are needed,
it appears that P450102A2 has a lower turnover rate than its relative BM3 in the
oxidation of straight chain fatty acids.
Table III.5. Enzymatic activity of P450 isoforms CYP102A2 and BM-3 with pNCA
CYP102A2 BM-3 wild-type18 BM-3 F87A18
Enzymatic activity
over 200 seconds
[kcat = (nmol of
product * nmol of
P450-1 * min-1)
4.24 114 508
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CHAPTER IV
CONCLUSIONS
13C NMR will be a powerful tool for probing the distribution of electrons in
cytochrome P450 enzymes. We have developed a novel expression system that allows for
high levels of 13C and 15N incorporation into the native heme of these enzymes. This will
eliminate the need to reconstitute apo-proteins with labeled exogenous heme as has
typically been done for other hemoproteins. E. coli Hu227 cells cannot synthesize their
own aminolevulinic acid, which is a heme precursor in the biosynthesis of the porphyrin
ring. This bacterial strain provided us with a way to selectively label the heme of any
hemoprotein we chose to overexpress, provided that the gene expression vector was
compatible with the Hu227 cells.
Cytochromes P450 have typically been expressed under the control of a T7
promoter in past studies. Such expression vectors are not compatible with Hu227 cells
because they do not carry a T7 polymerase. We chose dehaloperoxidase as a heme
containing model protein because it was under the control of a lac operon.
[4-13C] aminolevulinic acid, [5-13C] aminolevulinic acid, and [15N] aminolevulinic
acid were synthesized from the starting material glycine and characterized using 1H-
NMR with great success. These isotopomers were supplemented to E. coli Hu227 cells
for the labels to be incorporated into the heme of dehaloperoxidase (DHP). Although we
do not currently have the expertise to conduct the 13C-NMR studies ourselves, we were
successful in generating a highly concentrated (~1 mM) NMR sample of purified DHP.
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This DHP sample had been overexpressed in growth media supplemented with [5-13C]
ALA. Samples of DHP that had been overexpressed with the other two isotopomers of
ALA were also generated, but the stocks of these proteins were not large enough to
generate viable NMR samples.
Additionally, the LC-MS data of HPLC purified heme samples displayed masses
that were consistent with the incorporation of either eight 13C labels or four 15N labels,
depending on which isotopomer of ALA was supplied to the cells during overexpression.
These mass increases were precisely what were expected given that eight molecules of
aminolevulinic acid were required for the biosynthesis of a single heme molecule, and
that one nitrogen atom from each porphobilinogen (PBG) molecule was removed by PBG
deaminase during the heme biosynthesis as well.
Finally, we successfully generated a recombinant expression vector that contained
the CYP102A2 gene from Bacillus subtillis 168 that was under the control of a lac
promoter. This expression vector was shown to be compatible with the Hu227 cells and
displayed moderate expression in the whole cells (~ 200 nmol/ liter of culture). However,
the purification techniques of this enzyme need to be refined before isotopic labeling of
the heme can be done economically. The low activity of the enzyme that we observed
may be due to degradation of the protein. Multiple bands were observed from the protein
sample in the SDS-PAGE, and this suggests some protein degradation. Loss of the
reductase would significantly lower the activity of the enzyme. The recombinant
expression vector will provide a starting point for future 13C-NMR experiments to be
conducted on this cytochrome P450.
78
REFERENCES
1. Montellano, P. R. O. d. Cytochrome P450 Structure, Mechanism, and
Biochemistry third ed.; Kluwer Academic/Plenum Publishers: New York, 2005.
2. Guengerich, F. P. J. Biol. Chem. 1991, 266, 10019.
3. Silverman, R. B., The Organic Chemistry of Drug Design and Drug Action.
Second ed.; Elsevier Academic Press: 2006.
4. Rivera, M., Caignan, G. A., Anal. Bioanal. Chem. 2004, 378, 1464.
5. Alontaga, A. Y., Bunce, R.A., Wilkis, A., Rivera, M. Inorg. Chem. 2006, 45,
8876.
6. Eakanunkul, S. et al. Biochemistry 2005, 44, 13179.
7. Caignan, G.A.; Deshmukh, R.; Zeng, Y.; Wilks, A.; Bunce, R.A.; Rivera, M., J.
Am. Chem. Soc. 2003, 125, 11842.
8. Li, Juncheng; Deslouches, Berthony; Cosloy, Sharon D.; Russell, Charlotte
Sananes. Biochim. Biophys. Acta. 2003, 1626, 102.
9. Rivera, M., Walker, F.A. Anal. Biochem. 1995, 230, 295.
10. Wang, J., Scott, A.I. Tetrahedron Lett. 1997, 38, 739.
11. Nakamura, E., Aoki, Kouichi, S., Oshino, S.H., Kuwajima, I. J. Am. Chem. Soc.
1987, 109, 8056.
12. Chen, Y. P., Woodin, S.A., Lincoln, D.E., Lovell, C.R. J. Biol. Chem. 1996, 271,
4609.
13. LaCount, M. W., Zhang, E., Chen, Y.P., Han, K., Whitton, M.M., Lincoln, D.E.,
Woodin, S.A., Lebioda, L. J. Biol. Chem. 2000, 272, 18712.
14. Osborne, R. L., Taylor, L.O., Han, K.P., Ely, B., Dawson, J.H. Biochem. Biophys.
Res. Commun. 2004, 324, 1194.
15. Niehaus, K., Deng, P., Belyea, J., Franzen, S., Niehause, G.U. J. Phys. Chem. B.
2006, 110, 13264.
79
16. Osborne, R. L., Sumithran, S., Coggins, M.K., Chen, Y.P., Lincoln, D.E.,
Dawson, J.H. J. Inorg. Biochem. 2006, 100, 1100.
17. Gustafsson, M. C. U., Roitel, O., Marhsall, K.R., Noble, M.A., Chapman, S.K.,
Pessegueiro, A., Fulco, A.J., Chessma, M.R., Wachenfeldt, C., Munro, A.W.
Biochemistry 2004, 43, 5474.
18. Schwaneberg, U., Schmidt-Dannert, C., Schmitt, J., Schmid, R.D. Anal. Biochem.
1999, 269, 359.
19. Lussenburg, B. M. A., Babel, Lloyd C., Vermeulen, Nico P.E., Commandeur, Jan
N.M. Anal. Biochem. 2005, 341, 148.
20. Budde, M., Morr, Michael, Schmid, Rolf. D., Urlacher, Vlada B. Chem. Bio.
Chem. 2006, 7, 789.
21. Stratagene pBlueScript II Phagemid Vector.
http://www.stratagene.com/products/showProduct.aspx?pid=267
22. Omura, T.; Sato, R. J. Biol. Chem. 1964, 239, 2370.
23. Teale, F.W.J. (1959) Biochim. Biophys. Acta. 35, 543.
24. Yonetani, T. (1967), J. Biol. Chem. 242, 5008.
25. Kunst, F., Ogasawara, N., Moszer, I., Albertini, A. M., Alloni, G., et al. (1997),
Nature 390, 249.
26. Budde, M. M., S. C., Schmid, R. D. Appl. Microbiol. Biotechnol. 2005, 66, 180.
27. Roach, M. P., Chen, Y.P., Woodin, S.A., Lincoln, D.E., Lovell, C.R., Dawson,
J.H. Biochemistry 1997, 36, 2197.
28. Iida, K., Takao, Yuki, Ogai, Tomoe, Kajiwara, Masahiro J. Label. Compds.
Radiopharm. 1997, 797.
29. von Weymarn, L. B., Blobaum, A. L., Hollenberg, P.F. Arch. Biochem. Biophys.
2004, 425, 95.
30. Pflug, S., Richter, Sven M., Urlacher, Vlada B., J. Biotechnol. 2007.
doi:10.1016/j.jbiotec.2007.01.013
80
31. Maurer, S. C., Schulze, Holger, Schmid, Rolf D., Urlacher, Vlad, Adv. Synth.
Catal. 2003, 345, 802.
